Document:

Exhibit 10.3

 

 

SECURITIES PURCHASE AGREEMENT

 

BETWEEN

 

LILIUM N.V.

 

AND

 

THE INVESTORS NAMED HEREIN

 

 

 

 

Dated
as of November 18, 2022

 

 

    

     

    

 

This SECURITIES PURCHASE AGREEMENT (this “Agreement”)
is entered into on November 18, 2022, by and between Lilium N.V., a Dutch public limited liability company (naamloze vennootschap)
(“Lilium”), and each Investor identified on the signature pages hereto (each an “Investor”
and collectively the “Investors”). Certain terms used and not otherwise defined in the text of this Agreement
are defined in Section 7 hereof.

 

BACKGROUND

 

A.             Lilium
and the Investors desire to enter into this transaction relating to the offer and sale of the securities described herein pursuant to
a currently effective shelf registration statement on Form F-3 (File No. 333-267719) (the “Registration Statement”).

 

B.              Each
Investor wishes to purchase, and Lilium wishes to sell, upon the terms and conditions stated in this Agreement, (i) the number of
Lilium’s ordinary shares A, with a nominal value of €0.12 per share (the “Class A Ordinary Shares”),
set forth opposite such Investor’s name on Exhibit A hereto, which aggregate number of Class A Ordinary Shares
for all Investors together shall be $29,249,996.10 Class A Ordinary Shares (the “Shares”) and (ii) a
warrant to acquire up to that number of additional Class A Ordinary Shares set forth opposite such Investor’s name on Exhibit A
(collectively, the “Warrants” and, as exercised, the “Warrant Shares”), in substantially
the form attached hereto as Exhibit B. The Shares, the Warrants and the Warrant Shares collectively are referred to herein
as the “Securities”.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the foregoing
and the mutual representations, warranties and covenants herein contained, the parties hereto, intending to be bound, hereby agree as
follows:

 

1.             Sale
and Purchase of the Shares and Warrants. At Closing (as defined below), each Investor hereby agrees to purchase from Lilium, and
Lilium agrees to issue and sell to such Investor, the number of Shares set forth opposite such Investor’s name on Exhibit A
hereto at a purchase price of $1.30 per Share, on the terms and subject to the conditions provided for herein. At the Closing, upon
the terms and subject to the conditions set forth herein, Lilium hereby agrees to issue and sell to each Investor, and each Investor
agrees to purchase from Lilium, severally and not jointly, for no additional consideration, a Warrant exercisable for a number of Warrant
Shares set forth opposite such Investor’s name on Exhibit A hereto at an exercise price equal to $1.30 per Warrant
Share.

 

2.             Closing;
Payment of Purchase Price; Use of Proceeds.

 

2.1.           Closing.
The closing of the sale of the Shares and Warrants contemplated hereby (the “Closing”) shall occur on November 22,
2022 (the “Closing Date”). At the Closing, each Investor shall deliver to Lilium via wire transfer of U.S.
dollars in immediately available funds equal to the total purchase price set forth opposite such Investor’s name on Exhibit A
hereto and Lilium shall deliver to each Investor its respective Shares and Warrants in the amounts set forth opposite such Investor’s
name on Exhibit A hereto, deliverable at the Closing on the Closing Date, in accordance with this Section 2.1.
The Closing shall occur at 10:00 a.m. (New York City time) on the Closing Date remotely via the exchange of documents and signatures,
or such other time and location as the parties shall mutually agree. At the Closing, Lilium will deliver or cause its transfer agent
to deliver to each Investor or its designee (which may include an account of a participant of the Depository Trust Company that will
hold the Shares and Warrants for the account of Investor or its designee), a book-entry position for the Shares and Warrants purchased
by such Investor, registered in such Investor’s name. Such delivery shall be upon receipt of payment of the purchase price therefor
by such Investor by wire transfer of U.S. dollars in immediately available funds to Lilium in accordance with Lilium’s written
wiring instructions. Lilium will obtain from an EU licensed (branch of a) bank a statement confirming the EUR equivalent of the U.S.
dollar amount paid as purchase price to be at least equal to the aggregate nominal value in EUR of all Shares issued to such Investor.

 

    - 1 -

     

    

 

3.             Representations
and Warranties of the Investors. Each Investor hereby represents and warrants to Lilium, severally and not jointly, as follows:

 

3.1.           Organization.
The Investor has been duly formed or incorporated and is validly existing and is in good standing under the laws of its jurisdiction
of formation or incorporation, and has the requisite power and authority to enter into, deliver and perform its obligations under this
Agreement.

 

3.2.           Authorization;
Enforceability. The execution, delivery and performance by such Investor of this Agreement are within the powers of such Investor,
have been duly authorized and will not constitute or result in a breach or default under or conflict with any order, ruling or regulation
of any court or other tribunal or of any governmental commission or agency, or any agreement or other undertaking, to which such Investor
is a party or by which such Investor is bound (except for such breaches, default or conflicts that would not interfere with the Investor’s
ability to perform its obligations under this Agreement in any material respect), and will not violate any provisions of such Investor’s
organizational documents, including, without limitation, its incorporation or formation papers, bylaws, indenture of trust or partnership
or operating agreement, as may be applicable. The signature of such Investor on this Agreement is genuine, and the signatory has legal
competence and capacity to execute the same or the signatory has been duly authorized to execute the same, and, assuming that this Agreement
constitutes the valid and binding agreement of Lilium, this Agreement constitutes a legal, valid and binding obligation of such Investor,
enforceable against such Investor in accordance with its terms except as may be limited or otherwise affected by applicable bankruptcy,
insolvency or similar laws affecting creditors’ rights generally or by equitable principles relating to enforceability (collectively,
 “Bankruptcy Laws”).

 

3.3.           Brokers.
There is no investment banker, broker, finder, financial advisor or other person that has been retained by or is authorized to act on
behalf of such Investor and who is entitled to any fee or commission for which Lilium will be liable in connection with the transactions
contemplated by this Agreement.

 

    - 2 -

     

    

 

4.             Representations
and Warranties by Lilium. Lilium represents and warrants to each Investor that the statements contained in this Section 4
are complete and accurate as of the date of this Agreement.

 

4.1.           Issuance
of Securities; Registration Statement. The Shares are duly authorized and, when issued and delivered to each Investor against full
payment therefor in accordance with the terms of this Agreement, the Shares will be validly issued, fully paid and non-assessable and
free from all liens, charges, taxes, security interests, encumbrances, rights of first refusal, preemptive or similar rights and other
encumbrances with respect to the issue thereof. The Warrants have been duly authorized and, when executed and delivered by Lilium in
accordance with this Agreement, will constitute valid and legally binding agreements of Lilium enforceable against Lilium in accordance
with their terms, except as enforceability may be limited or otherwise affected by applicable Bankruptcy Laws. The Warrant Shares to
be issued by Lilium upon exercise of the Warrants, as provided therein, have been duly authorized and, when issued and delivered upon
exercise as provided under the Warrant, will be duly and validly issued, fully paid and non-assessable and free from all liens, charges,
taxes, security interests, encumbrances, rights of first refusal, preemptive or similar rights and other encumbrances with respect to
the issue thereof. The Registration Statement is effective and available for the issuance of the Securities thereunder. Lilium has not
received any notice that the Commission has issued or intends to issue a stop-order with respect to the Registration Statement or that
the Commission otherwise has suspended or withdrawn the effectiveness of the Registration Statement, either temporarily or permanently,
or, to the knowledge of Lilium, no proceeding for that purpose or pursuant to Section 8A of the Securities Act against Lilium has
been initiated or threatened by the Commission and no notice of objection of the Commission to the use of such Registration Statement
pursuant to Rule 401(g)(2) under the Securities Act has been received by Lilium. Upon receipt of the Securities, the Investors
will have good and marketable title to the Securities. Any reference herein to the Registration Statement shall be deemed to refer to
and include the documents incorporated by reference therein pursuant to Item 6 of Form F-3 which were filed under the Exchange Act
on or before the effective date of the Registration Statement, and any reference herein to the terms “amend,” “amendment”
or “supplement” with respect to the Registration Statement shall be deemed to refer to and include the filing of any document
under the Exchange Act after the effective date of the Registration Statement deemed to be incorporated therein by reference. The Registration
Statement, when it became effective and, as of the date of any amendment or supplement thereto, complied in all material respects with
the applicable requirements of the Securities Act, and each of the documents incorporated by reference, as of the date hereof, in the
Registration Statement (collectively, the “Incorporated Documents”), as of the date each such Incorporated
Document was filed with the Commission, complied in all material respects with the applicable requirements of the Exchange Act. The Registration
Statement did not, as of the effective date, and will not contain any untrue statement or a material fact or omit to state any material
fact required to be stated therein or necessary in order to make the statements therein not misleading. As of the date of this Agreement,
Lilium satisfies the eligibility requirements for use of Form F-3 under the Securities Act, and has prepared and filed with the
Commission a shelf registration statement, as defined in Rule 405, on Form F-3 (File No. 333-267719).

 

    - 3 -

     

    

 

4.2.           Financial
Statements. The financial statements and the related notes thereto included or incorporated by reference in the Registration Statement,
or any prospectus relating thereto, complied as to form in all material respects with the applicable requirements of the Securities Act
and the Exchange Act in effect as of the time of filing and present fairly in all material respects the financial condition of Lilium
as of the dates shown and its results of operations, cash flows and changes in stockholders’ equity for the periods shown, and
such consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (the “IFRS”),
as issued by the International Accounting Standards Board and the related interpretations issued by the IFRS Interpretations Committee
and applied on a consistent basis throughout the periods covered thereby except for any normal adjustments in Lilium’s financial
statements. The other financial and statistical data with respect to Lilium contained or incorporated by reference in the Registration
Statement are accurately and fairly presented and prepared on a basis consistent with the audited financial statements included or incorporated
by reference in the Registration Statement and books and records of Lilium; there are no financial statements (historical or pro
forma) that are required to be included or incorporated by reference in the Registration Statement that are not included or incorporated
by reference as required. All disclosures contained or incorporated by reference in the Registration Statement, if any, regarding “non-IFRS
financial measures” (as such term is defined by the rules and regulations of the Commission) comply in all material respects
with Regulation G under the Exchange Act and Item 10 of Regulation S-K under the Securities Act, to the extent applicable. Lilium does
not have any material liabilities or obligations, direct or contingent, not described in the Registration Statement, which are required
to be described in the Registration Statement.

 

4.3.           Capitalization.
The authorized share capital of Lilium and the shares comprised in that authorized share capital that are issued and outstanding were
in all material respects as set forth in the Registration Statement as of the date reflected therein. All of the outstanding shares in
the capital of Lilium have been duly authorized and validly issued, and are fully paid and non-assessable. Except as set forth in the
Registration Statement and this Agreement, there are no agreements or arrangements under which Lilium is obligated to register the sale
of any securities under the Securities Act. Except as set forth in the Registration Statement, no shares comprised in the authorized
share capital of Lilium are subject to preemptive rights, rights of first refusal or other similar rights and there are no outstanding
debt securities and no contracts, commitments, understandings, or arrangements by which Lilium is or may become bound to issue additional
shares in the the capital of Lilium or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities or rights convertible into or exchangeable for, any shares in the capital of Lilium other than those issued
or granted in the ordinary course of business pursuant to Lilium’s equity incentive and/or compensatory plans or arrangements.

 

4.4.           Incorporation
and Good Standing of Lilium. Lilium and each of its subsidiaries (each a “Subsidiary” and together, “Subsidiaries”)
is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its
incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business
as currently conducted. Neither Lilium nor any Subsidiary is in violation nor default of any of the provisions of its respective charter
or by-laws or similar organizational documents (collectively, “Organizational Documents”). Each of Lilium and
the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction
in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to
be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in (i) a material adverse
effect on the business, financial condition or results of operations of Lilium and its Subsidiaries, taken as a whole (a “Material
Adverse Effect”) or (ii) any change or development that could reasonably be expected to have a Material Adverse Effect
on the performance of this Agreement or the consummation of any of the transactions contemplated hereby, and no action, lawsuit, complaint,
claim, petition, suit, audit, examination, assessment, arbitration, mediation or inquiry, or any proceeding or investigation, by or before
any governmental authority has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit
or curtail such power and authority or qualification.

 

    - 4 -

     

    

 

4.5.           Consents.
Except as specifically contemplated by this Agreement and as required under the Securities Act or the Exchange Act (including, without
limitation, filing with the Commission the prospectus supplement pursuant to Rule 424(b) under the Securities Act (the “Prospectus
Supplement”) supplementing the base prospectus forming part of the Registration Statement (together, the “Prospectus”)
and a Current Report on Form 6-K) and any applicable state securities laws, Lilium is not required under any federal, state, local
or foreign law, rule or regulation to obtain any consent, authorization or order of, or make any filing or registration with, any
court governmental agency or regulator (including, without limitation, the Nasdaq Global Select Market (“Nasdaq”))
in order for it to execute, deliver or perform any of its obligations under the Transaction Documents, or to issue the Securities to
each Investor in accordance with the terms thereof (other than such consents, authorizations, orders, filings or registrations as have
been, or will be, obtained or made prior to the Closing Date).

 

4.6.           Authorization;
Enforcement. Lilium has the requisite corporate power and authority to enter into and perform its obligations under the Transaction
Documents and to issue the Securities in accordance with the terms thereof. Except for approvals of Lilium’s board of directors
or a committee thereof as may be required in connection with any issuance and sale of Securities to each Investor hereunder (which approvals
shall be obtained prior to the delivery of any Securities), the execution, delivery and performance by Lilium of the Transaction Documents
and the consummation by it of the transactions contemplated thereby have been duly and validly authorized by all necessary corporate
action, and no further consent or authorization of Lilium, its board of directors or its shareholders is required. The Transaction Documents
have been (or upon delivery will have been) duly executed and delivered by Lilium and constitute a valid and binding obligation of Lilium
enforceable against Lilium in accordance with their terms, except as such enforceability may be limited by applicable Bankruptcy Laws.

 

4.7.           No
Conflicts. The execution, delivery and performance by Lilium of the Transaction Documents and the consummation by Lilium of the transactions
contemplated thereby do not and shall not (i) result in a violation of any provision of Lilium’s Organizational Documents,
(ii) result in a breach or violation of any of the terms or provisions of, or constitute a default (or an event which, with notice
or lapse of time or both, would become a default) under, or give rise to any rights of termination, amendment, acceleration or cancellation
of, any contract, agreement or plan which would be required to be filed with the Commission as an exhibit to an annual report on Form 20-F,
mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument or obligation to which Lilium or any of its Subsidiaries
is a party or is bound, (iii) create or impose a lien, charge or encumbrance on any property or assets of Lilium or any of its Subsidiaries
under any agreement or any commitment to which Lilium or any of its Subsidiaries is a party or by which Lilium or any of its Subsidiaries
is bound or to which any of their respective properties or assets is subject, or (iv) result in a violation of any federal, state,
local or foreign statute, rule, regulation, order, judgment or decree applicable to Lilium or any of its Subsidiaries or by which any
property or asset of Lilium or any of its Subsidiaries are bound or affected, except, in the case of clauses (ii), (iii) and (iv),
for such conflicts, defaults, terminations, amendments, acceleration, cancellations, liens, charges, encumbrances and violations as would
not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect.

 

    - 5 -

     

    

 

4.8.           Brokers.
There is no investment banker, broker, finder, financial advisor or other person that has been retained by or is authorized to act on
behalf of Lilium and who is entitled to any fee or commission in connection with the transactions contemplated by the Transaction Documents
other than fees or commissions payable to each of Citigroup Global Markets Inc., B. Riley Securities, Inc. and Piper Sandler &
Co. who are serving as placement agents in connection with the issuance and sale of the Securities pursuant to this Agreement and whose
fees shall be the sole responsibility of Lilium.

 

4.9.           Lock-Up
Agreements. Each of the persons listed on Exhibit C hereto has executed and delivered to Citigroup Global Markets Inc.
and Piper Sandler & Co. a lock-up agreement substantially in the form of Exhibit D hereto. Exhibit C
hereto contains a true, complete and correct list of all directors and executive officers of Lilium.

 

4.10.         Investment
Company Act. Lilium is not, and as a result of the consummation of the transactions contemplated by the Transaction Documents and
the application of the proceeds from the sale of the Securities as will be set forth in the Registration Statement (and any post-effective
amendment thereto), will not be an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

 

4.11.         No
Unlawful Payments. Neither Lilium nor any of its Subsidiaries nor any director or officer, nor, to the knowledge of Lilium, any employee,
agent, representative or Affiliate or other Person acting on behalf of Lilium or any of its Subsidiaries has, in the course of its actions
for, or on behalf of, Lilium or any of its Subsidiaries (i) used any corporate funds for any unlawful contribution, gift, entertainment
or other unlawful expenses relating to political activity; (ii) taken any action in furtherance of an offer, payment, promise
to pay, or authorization or approval of the payment or giving of money, property, gifts or anything else of value, directly or indirectly,
to any “government official” (including any officer or employee of a government or government-owned or controlled entity
or of a public international organization, or any Person acting in an official capacity for or on behalf of any of the foregoing, or
any political party or party official of any federal, state or foreign office or candidate for any federal, state or foreign political
office) to improperly influence official action or secure an improper advantage (to the extent acting on behalf of or providing services
to Lilium); (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the
 “FCPA”), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv) made,
offered, authorized, requested, or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or
other unlawful payment or benefit. Lilium and its Subsidiaries and, to the knowledge of Lilium, Lilium’s Affiliates have conducted
their businesses in compliance with the FCPA, any applicable law or regulation implementing the OECD Convention on Combating Bribery
of Foreign Public Officials in International Business Transactions, signed December 17, 1997, the U.K. Bribery Act 2010 and other
applicable anti-corruption, anti-money laundering and anti-bribery laws, and have instituted and maintain policies and procedures designed
to promote and achieve compliance with such laws and with the representation and warranty contained herein.

 

    - 6 -

     

    

 

4.12.         No
Conflicts with Sanction Laws. Neither Lilium nor any of its Subsidiaries, nor any director or officer thereof, nor, to Lilium’s
knowledge, any employee, agent, Affiliate or representative of Lilium, is a Person that is, or is majority owned or controlled by a Person
that is (i) named on the Specially Designated Nationals and Blocked Persons List, the Foreign Sanctions Evaders List, the Sectoral
Sanctions Identification List, or any other similar list of sanctioned persons (collectively, “Sanction Lists”)
administered by the U.S. Treasury Department’s Office of Foreign Assets Control (“OFAC”), or any similar
list of sanctioned persons administered by the U.S. Department of State, the United Nations Security Council, the European Union, His
Majesty’s Treasury of the United Kingdom, any individual European Union member state, including the United Kingdom or other relevant
sanctions authority, nor (ii) located, organized or resident of the Crimea Region of Ukraine, the so-called Donetsk People’s
Republic, the so-called Luhansk People’s Republic, Cuba, Iran, North Korea, Sudan or Syria, or any other country (each a “Sanction
Country” and collectively, “Sanction Countries”) or territory embargoed or subject to substantial
trade restrictions by the United States, the European Union or any individual European Union member state, including the United Kingdom.
Neither Lilium nor any of its Subsidiaries will, directly or indirectly, use the proceeds from the sale of Securities under the Transaction
Documents, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other Person (a) to
fund or facilitate any activities or business of or with any Person or any Sanctioned Country, or (b) in any other manner that will
result in a violation of Sanction Lists by any Person (including any Person participating in the offering of the Securities, whether
as underwriter, advisor, investor or otherwise). For the past five (5) years, neither Lilium nor any of its Subsidiaries have knowingly
engaged in, or are now knowingly engaged in, any dealings or transactions with any Person that at the time of the dealing or transaction
is or was the subject of Sanction Lists or a Sanction Country.

 

5.             Covenants.

 

5.1.           Prospectus
Supplement. As soon as practicable after execution of this Agreement, Lilium shall file the Prospectus Supplement with respect to
the Securities as required under, and in conformity with, the Securities Act, including Rule 424(b) thereunder. Without limiting
any other obligation of Lilium under this Agreement, Lilium shall timely make all filings and reports relating to the offer and sale
of the Securities required under all applicable securities laws (including, without limitation, all applicable federal securities laws
and all applicable “Blue Sky” laws), and Lilium shall comply with all applicable federal, state and local laws, statutes,
rules and regulations relating to the offering and sale of the Securities to the Investor. Lilium shall use its reasonable best
efforts to take all necessary action to ensure the compliance with all applicable securities laws (including without limitation “Blue
Sky” laws) of the issuance of any Warrant Shares from time to time upon exercise of the Warrants.

 

    - 7 -

     

    

 

5.2.           Securities
Laws Disclosure; Publicity. Lilium shall, by 9:00 a.m. (New York City time) on the first business day following the date hereof,
issue one or more press releases or furnish or file with the Commission a current report on Form 6-K (collectively, the “Disclosure
Document”) disclosing, to the extent not previously publicly disclosed, the transactions contemplated hereby, all material
terms thereof and any other material, non-public information that Lilium has provided to any Investor at any time prior to the filing
of the Disclosure Document. Prior to the Disclosure Document, the parties shall keep the transactions contemplated hereby confidential,
and no party shall make any public announcement regarding the transactions contemplated hereby. From and after the disclosure of the
Disclosure Document, to the knowledge of Lilium, except as noted above, no Investor shall be in possession of any material, non-public
information received from Lilium or its officers, directors, employees or agents.

 

5.3.           Reservation
of Class A Ordinary Shares; Listing. Lilium shall reserve, and continue to reserve and keep available at all times, free of
preemptive rights, a sufficient number of Class A Ordinary Shares for the purpose of enabling Lilium to issue all of the Warrant
Shares. On the Closing Date, the Shares shall be listed on Nasdaq; and Lilium shall use its reasonable best effort to cause the Warrant
Shares, when issued, to be listed on Nasdaq or such other securities exchange on which the Shares are then listed for trading.

 

5.4.           Clear
Market. Lilium will not, without the prior written consent of Citigroup Global Markets Inc., B. Riley Securities, Inc. and Piper
Sandler & Co., offer, sell, contract to sell, pledge, or otherwise dispose of (or enter into any transaction which is designed
to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due
to cash settlement or otherwise) by Lilium or any of the Subsidiaries) directly or indirectly, including the filing (or participation
in the filing) of a registration statement with the Commission in respect of, or establish or increase a put equivalent position or liquidate
or decrease a call equivalent position within the meaning of Section 16 of the Exchange Act, any other Class A Ordinary Shares
or any securities convertible into, or exercisable, or exchangeable for, any capital stock of Lilium, including, without limitation,
Class A Ordinary Shares; or publicly announce an intention to effect any such transaction, for a period of thirty (30) days after
the date of this Agreement, provided, however, that Lilium may (i) grant, issue and settle options, restricted stock awards, stock
units or any other type of equity award, including Class A Ordinary Shares, pursuant to any employee stock option plan, stock ownership
plan, incentive awards plan or dividend reinvestment plan of Lilium in effect as of the date of this Agreement and file any registration
statement on Form S-8 if necessary or required in connection with such plans, (ii) issue Class A Ordinary Shares upon
the conversion of securities or the exercise of warrants outstanding as of the date of this Agreement, (iii) effect any conversion
of any class of Lilium’s capital stock, issuance, or other action required under or needed to effectuate any director’s or
officer’s 10b5-1 plan, but only to the extent such plan was in effect prior to the date hereof and disclosed to Citigroup Global
Markets Inc. and Piper Sandler & Co., (iv) file any registration statement on Form F-3 and prospectus or prospectus
supplement related to the resale of securities as may be required pursuant to private placement agreements executed on or prior to the
date hereof, and cause such registration to become effective, or (v) sell, issue or enter into an agreement to sell or issue, Class A
Ordinary Shares or securities convertible into or exercisable for Class A Ordinary Shares to a supplier, vendor, or other business
partner of Lilium pursuant to procurement or similar arrangements or in exchange for the cancellation or extinguishment of any obligation
or liability of Lilium or any of its Subsidiaries (current or future) with such supplier, vendor, or other business partner, or pursuant
to any agreement with such supplier, vendor or other business partner in effect on the date hereof, or otherwise, or file any registration
statement on Form F-3, prospectus or prospectus supplement related to the resale of securities as may be required under securities
purchase agreements with such supplier, vendor, or other business partner and cause such registration statement to become effective.

 

    - 8 -

     

    

 

6.             Conditions
to Obligations of the Investors and Lilium. The respective obligations of Lilium, on the one hand, and each Investor, on the other
hand, to consummate the purchase and sale of the Securities pursuant to this Agreement is subject to the condition that all representations
and warranties of Lilium (with respect to the obligations of the Investors) and the Investors (with respect to the obligations of Lilium)
contained in this Agreement shall be true and correct in all material respects on and as of the date hereof and on and as of the Closing
Date (unless they specifically speak as of another date in which case they shall be true and correct in all material respects as of such
date) (other than representations and warranties that are qualified as to materiality or Material Adverse Effect, which representations
and warranties shall be true and correct in all respects); provided that (with respect to the obligations of the Investors) the representations
and warranties of Lilium contained in Section 4 of this Agreement shall be true and correct in all respects on and as of the date
hereof and on and as of the Closing Date and (with respect to the obligations of Lilium) the representations and warranties of each Investor
(solely with respect to such Investor’s power and authority) shall be true and correct in all respects on and as of the date hereof
and on and as of the Closing Date.

 

7.             Definitions.
Unless the context otherwise requires, the terms defined in this Section 7 shall have the meanings specified for all purposes
of this Agreement.

 

“Affiliate” shall have
the meaning ascribed to such term in Rule 12b-2 promulgated under the Exchange Act.

 

“Agreement” has the meaning
assigned to it in the introductory paragraph hereof.

 

“Closing” has the meaning
assigned to it in Section 2.1 hereof.

 

“Closing Date” has the
meaning assigned to it in Section 2.1 hereof.

 

“Commission” means the
Securities and Exchange Commission.

 

“Class A Ordinary Shares”
has the meaning assigned to it in the recitals hereof.

 

    - 9 -

     

    

 

“Exchange Act” means the
Securities Exchange Act of 1934, as amended.

 

“Person” means and includes
all natural persons, corporations, business trusts, associations, companies, partnerships, joint ventures, limited liability companies
and other entities and governments and agencies and political subdivisions.

 

“Prospectus”
has the meaning assigned to it in Section 4.5 hereof.

 

“Prospectus Supplement”
has the meaning assigned to it in Section 4.5 hereof.

 

“Incorporated Documents”
has the meaning assigned to it in Section 4.1 hereof.

 

“Investor” and “Investors”
have the meaning assigned to them in the introductory paragraph of this Agreement and shall include any Affiliates of the Investors.

 

“Registration Statement”
has the meaning assigned to it in the recitals hereof.

 

“Securities” has the meaning
assigned to it in the recitals hereof.

 

“Securities Act” means
the Securities Act of 1933, as amended.

 

“Subsidiary” has the meaning
assigned to it in Section 4.4 hereof.

 

“Transaction Documents”
means this Agreement and the Warrants.

 

“Warrant” has the meaning
assigned to such term in the recitals hereof.

 

“Warrant Shares” has the
meaning assigned to it in the recitals hereof.

 

8.             Survival.
The representations, warranties, covenants, indemnities and agreements contained in the Transaction Documents shall survive Closing of
the transactions contemplated by this Agreement.

 

9.             Miscellaneous.

 

9.1.           Amendments.
Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular
instance and either retroactively or prospectively), only with the written consent of Lilium and each Investor.

 

9.2.           Notices.
All notices, requests, consents, and other communications under this Agreement shall be in writing. Any notices, requests, demands and
other communications required or permitted in this Agreement shall be effective if in writing and (i) delivered personally, (ii) sent
by e-mail or (iii) delivered by overnight courier, in each case, addressed as follows:

 

    - 10 -

     

    

 

If to Lilium to:

 

Lilium N.V.

c/o Lilium Aviation Inc.

2385 N.W. Executive Center Drive, Suite 300

Boca Raton, Florida 33431

Attention: Roger Franks

Email: roger.franks@lilium.com

 

with copies (which shall not constitute notice)
to:

 

Ropes & Gray LLP

1211 Avenue of the Americas

New York, NY 10036-8704

Attention: Carl Marcellino

Email: carl.marcellino@ropesgray.com

 

Freshfields Bruckhaus Deringer US LLP

601 Lexington Avenue

New York, NY 10022

Attention: Valerie Ford Jacob

Email: valerie.jacob@freshfields.com

 

If to an Investor:

 

To the address set forth on the Investor’s signature
page hereto;

 

or at such other address as Lilium or such Investor each may specify
by written notice to the other parties hereto. Any party may change the address to which notices, requests, consents or other communications
hereunder are to be delivered by giving the other parties notice in the manner set forth in this Section 9.2.

 

9.3.           No
Waivers. No failure or delay by any party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor shall
any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right or power,
or any course of conduct, preclude any other or further exercise thereof or the exercise of any other right or power. The rights and
remedies of the parties and third party beneficiaries hereunder are cumulative and are not exclusive of any rights or remedies that they
would otherwise have hereunder.

 

9.4.           Successors
and Assigns. Except as otherwise provided herein, this Agreement shall be binding upon, and inure to the benefit of the parties hereto
and their heirs, executors, administrators, successors, legal representatives, and permitted assigns, and the agreements, representations,
warranties, covenants and acknowledgments contained herein shall be deemed to be made by, and be binding upon, such heirs, executors,
administrators, successors, legal representatives and permitted assigns.

 

    - 11 -

     

    

 

9.5.           Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.

 

9.6.           Governing
Law. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO
THE PRINCIPLES OF CONFLICTS OF LAWS THAT WOULD OTHERWISE REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER STATE.

 

9.7.           Jurisdiction.
THE PARTIES HERETO IRREVOCABLY SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF
NEW YORK AND THE SUPREME COURT OF THE STATE OF NEW YORK SOLELY IN RESPECT OF THE INTERPRETATION AND ENFORCEMENT OF THE PROVISIONS OF
THE TRANSACTION DOCUMENTS AND IN RESPECT OF THE TRANSACTIONS CONTEMPLATED THEREBY, AND HEREBY WAIVE, AND AGREE NOT TO ASSERT, AS A DEFENSE
IN ANY ACTION, SUIT OR PROCEEDING FOR INTERPRETATION OR ENFORCEMENT HEREOF OR ANY SUCH DOCUMENT THAT IS NOT SUBJECT THERETO OR THAT SUCH
ACTION, SUIT OR PROCEEDING MAY NOT BE BROUGHT OR IS NOT MAINTAINABLE IN SAID COURTS OR THAT VENUE THEREOF MAY NOT BE APPROPRIATE
OR THAT THE TRANSACTION DOCUMENTS OR ANY SUCH DOCUMENT MAY NOT BE ENFORCED IN OR BY SUCH COURTS, AND THE PARTIES HERETO IRREVOCABLY
AGREE THAT ALL CLAIMS WITH RESPECT TO SUCH ACTION, SUIT OR PROCEEDING SHALL BE HEARD AND DETERMINED BY SUCH A NEW YORK STATE OR FEDERAL
COURT. THE PARTIES HEREBY CONSENT TO AND GRANT ANY SUCH COURT JURISDICTION OVER THE PERSON OF SUCH PARTIES AND OVER THE SUBJECT MATTER
OF SUCH DISPUTE AND AGREE THAT MAILING OF PROCESS OR OTHER PAPERS IN CONNECTION WITH SUCH ACTION, SUIT OR PROCEEDING IN THE MANNER PROVIDED
IN SECTION 9.2 OF THIS AGREEMENT OR IN SUCH OTHER MANNER AS MAY BE PERMITTED BY LAW SHALL BE VALID AND SUFFICIENT SERVICE
THEREOF.

 

9.8.           Waiver
of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THE TRANSACTION DOCUMENTS OR THE
TRANSACTIONS CONTEMPLATED THEREBY IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY
AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY
ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES
THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY
WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER; (II) SUCH PARTY UNDERSTANDS AND HAS CONSIDERED
THE IMPLICATIONS OF THE FOREGOING WAIVER; (III) SUCH PARTY MAKES THE FOREGOING WAIVER VOLUNTARILY; AND (IV) SUCH PARTY HAS
BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVER AND CERTIFICATIONS IN THIS SECTION 9.8.

 

    - 12 -

     

    

 

9.9.           Counterparts;
Effectiveness. This Agreement may be executed in one or more counterparts (including by electronic mail or in .pdf) and by different
parties in separate counterparts, with the same effect as if all parties hereto had signed the same document. All counterparts so executed
and delivered shall be construed together and shall constitute one and the same agreement.

 

9.10.         Entire
Agreement. The Transaction Documents (including the exhibits and schedules thereto) constitutes the entire agreement, and supersedes
all other prior agreements, understandings, representations and warranties, both written and oral, among the parties, with respect to
the subject matter thereof.

 

9.11.         Severability.
If any provision of this Agreement shall be adjudicated by a court of competent jurisdiction to be invalid, illegal or unenforceable,
the validity, legality or enforceability of the remaining provisions of this Agreement shall not in any way be affected or impaired thereby
and shall continue in full force and effect.

 

[Remainder of Page Intentionally Left
Blank]

 

    - 13 -

     

    

 

IN WITNESS WHEREOF, the parties hereto have caused
this Agreement to be duly executed as of the day and year first above written.

 

Lilium:

 

	 	LILIUM N.V.
	 	 
	 	 
	 	By:	       
	 	Name:
	 	Title:

 

[Signature Page to Securities
Purchase Agreement]

 

     

     

    

 

Investor:

 

	Name of Investor:

    [Name of Investor]

    

    

    
	 	State/Country of Formation or Domicile:

    [ ]

	 	 	 
	 	 	 
	By:	                  	 	By:	                 
	Name:	 	 	Name:	 
	Title:	 	 	Title:	 
	 	 	 
	Name in which Securities are to be registered (if different):

     
	 	Date: November      , 2022
	EIN:	 	Broker Name:

     

    Broker DTC #:

	 	 	 
	Business Address-Street:

     
	 	Mailing Address-Street (if different):
	City, State, Zip:

     
	 	City, State, Zip:
	Attn:
	 
	 	Attn:
	 

	 	 	 
	 	 	 
	Telephone No.:

    Facsimile No.:
	 	Telephone No.:

    Facsimile No.:

 

[Signature Page to Securities Purchase Agreement]

 

     

     

    

 

EXHIBIT A

 

	Investor	 	Class A
 Ordinary

    Shares to 
 be 
 Purchased	 	Number of
 Warrant
    
 Shares 
 Underlying 
 Warrant	 	Aggregate Purchase

    Price
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	Total	 	 	 	 	 	 

 

[Signature Page to Securities Purchase Agreement]Exhibit 10.4

 

PLACEMENT AGENCY AGREEMENT

 

November 18, 2022

 

Citigroup Global Markets Inc.

388 Greenwich St.

New York, New York 10013

 

B. Riley Securities, Inc.

299 Park Avenue, 21st Floor

New York, New York 10171

 

Piper Sandler & Co.

1251 Avenue of the Americas, 6th Floor

New York, New York 10020

 

Ladies and Gentlemen:

 

Lilium N.V., a Dutch public limited liability company
(naamloze vennootschap) (the “Company”), proposes, subject to the terms and conditions of this Placement Agency
Agreement (the “Agreement”) and the Purchase Agreements (as defined in Section 1(a) hereof), to sell to certain
investors (each, an “Investor” and collectively, the “Investors”) an aggregate of (i) 22,499,997
Class A ordinary shares, nominal value €0.12 per share (the “Class A Ordinary Shares”), of the Company
(the “Shares”) and (ii) warrants, in the form of Exhibit A attached hereto, to purchase Class A Ordinary
Shares (the “Warrants”), in an offering under the Company’s registration statement on Form F-3 (Registration
No. 333-267719). The Shares, the Warrants and the Class A Ordinary Shares issuable upon exercise of the Warrants (the “Warrant
Shares”) are collectively referred to herein as the “Securities”. For purposes of this Agreement, except
where otherwise expressly provided, capitalized terms shall have the meanings set forth in Section 14 hereof.

 

1.            Agreement
to Act as Placement Agents.

 

The Company hereby confirms its agreement with you
as follows:

 

(a)            On
the basis of the representations, warranties and agreements of the Company contained herein, and subject to all the terms and conditions
of this Agreement, Citigroup Global Markets Inc. (“Citigroup”), B. Riley Securities, Inc. (“B. Riley”)
and Piper Sandler & Co. (“Piper”) shall be the Company’s exclusive placement agents (the “Placement
Agents”), each acting on a reasonable best efforts basis, in connection with the sale by the Company of the Securities to the
Investors in a proposed offering pursuant to the Registration Statement, with the terms of the offering to be subject to market conditions
and negotiations among the Company and the prospective Investors (such offering shall be referred to herein as the “Offering”).
As compensation for services rendered, and provided that any of the Securities are sold to Investors in the Offering, on the Closing Date
(as defined in Section 1(c) hereof) of the Offering, the Company shall pay to the Placement Agents a cash fee equal to six percent
(6.0%) of the aggregate gross proceeds raised in the Offering at the Closing (the “Placement Fee”). The sale of the
Securities shall be made pursuant to securities purchase agreements between the Company and the Investors in the form included as Exhibit B
hereto (each, a “Purchase Agreement” and collectively, the “Purchase Agreements”) on the terms described
on Exhibit C hereto. This Agreement, the Warrants and the Purchase Agreements are collectively referred to as the “Transaction
Documents”. Each Placement Agent shall communicate to the Company, orally or in writing, each offer to purchase Securities received
by such Placement Agent. The Company shall have the sole right to accept offers to purchase the Securities and may reject any such offer
in whole or in part.

 

     

     

    

 

(b)            This
Agreement shall not give rise to any commitment by the Placement Agents to purchase any of the Securities, and the Placement Agents shall
have no authority to bind the Company to accept offers to purchase the Securities. Each Placement Agent represents and agrees that it
has not made and will not make any offer relating to the Securities that would constitute a Free Writing Prospectus that would be required
to be filed with the Commission. Each Placement Agent may, with the prior consent of the Company (such consent not to be unreasonably
withheld), retain other brokers or dealers to act as sub-agents on its behalf in connection with the Offering, the fees of which shall
be paid out of such Placement Agent’s portion of the Placement Fee. Each of the Placement Agents agrees that it will use its reasonable
best efforts to conduct the Offering in compliance with this Agreement and the requirements of applicable law.

 

(c)            Payment
of the purchase price for, and delivery of, the Securities shall be made at a closing (the “Closing”) by email exchange
of documentation at 10:00 a.m., New York City time, on or before November 22, 2022, or at such time on such other date as may be
agreed upon in writing by the Placement Agents and the Company (such date of payment and delivery being herein called the “Closing
Date”). All such actions taken at the Closing shall be deemed to have occurred simultaneously. No Securities which the Company
has agreed to sell pursuant to the Purchase Agreements shall be deemed to have been purchased and paid for, or sold by the Company, until
such Securities shall have been delivered to the Investor thereof against payment therefor by such Investor. If the Company shall default
in its obligations to deliver the Securities to an Investor whose offer it has accepted, the Company shall indemnify and hold the Placement
Agents harmless against any loss, claim or damage incurred by the Placement Agents arising from or as a result of such default by the
Company.

 

(d)            On
the Closing Date, (i) the Company shall deliver, or cause to be delivered, the Securities to the Investors or their respective designees,
and the Investors shall deliver, or cause to be delivered, the purchase price for their respective Securities to the Company pursuant
to the terms of the Purchase Agreements, “delivery versus payment” through the facilities of The Depository Trust Company
(“DTC”) and (ii) the Company shall wire the amounts owed to the Placement Agents as provided in this Agreement.

 

(e)            The
Securities shall be registered in such names and in such denominations as each Investor shall request by written notice to the Company.

 

(f)            The
Company acknowledges and agrees that the Placement Agents are acting solely in the capacity of an arm’s length contractual counterparty
to the Company with respect to the Offering contemplated hereby (including in connection with determining the terms of the Offering) and
not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally, the Placement Agents are
not advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The
Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation
and appraisal of the transactions contemplated hereby, and the Placement Agents shall have no responsibility or liability to the Company
with respect thereto. Any review by the Placement Agents of the Company, the transactions contemplated hereby or other matters relating
to such transactions will be performed solely for the benefit of the Placement Agents and shall not be on behalf of the Company.

 

    	 	2	 

     

    

 

2.            Representations,
Warranties and Agreements of the Company. The Company represents and warrants to, and agrees with, the Placement Agents as of the
date hereof, and as of the Closing Date, as follows:

 

(a)            The
Company meets the requirements for use of Form F-3 under the Securities Act of 1933, as amended, and the rules and regulations
thereunder (collectively, the “Act”) and has prepared and filed with the Commission a shelf registration statement,
as defined in Rule 405 (file number 333-267719) on Form F-3, including a related Base Prospectus, for registration under the
Act of the offering and sale of the Securities. The Company will file with the Commission a Final Prospectus Supplement relating to the
Securities in accordance with Rule 424(b). The Registration Statement, at the Execution Time, is effective and meets the requirements
set forth in Rule 415(a)(1)(x). There is no stop order suspending the effectiveness of the Registration Statement, the use of the
Base Prospectus or the Final Prospectus Supplement, and, to the knowledge of the Company, no proceeding for that purpose or pursuant to
Section 8A of the Act against the Company or related to the Offering has been initiated or threatened by the Commission and no notice
of objection of the Commission to the use of such Registration Statement pursuant to Rule 401(g)(2) under the Act has been received
by the Company. Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus Supplement or the
Final Prospectus Supplement shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 6
of Form F-3 which were filed under the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder
(collectively, the “Exchange Act”) on or before the Effective Date of the Registration Statement or the issue date
of the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement, as the case may be; and any reference
herein to the terms “amend,” “amendment” or “supplement” with respect to the Registration Statement,
the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement shall be deemed to refer to and include
the filing of any document under the Exchange Act after the Effective Date of the Registration Statement or the issue date of the Base
Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement, as the case may be, deemed to be incorporated therein
by reference.

 

(b)            On
each Effective Date, the Registration Statement did, and when the Final Prospectus Supplement is filed in accordance with Rule 424(b) and
on the Closing Date, the Final Prospectus Supplement (and any amendment or supplement thereto) will, comply in all material respects with
the applicable requirements of the Act and the Exchange Act and the respective rules thereunder; on each Effective Date and
at the Execution Time, the Registration Statement did not and will not contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary in order to make the statements therein not misleading; and on the date
of any filing pursuant to Rule 424(b); and on the Closing Date, the Final Prospectus Supplement (together with any amendment
or supplement thereto) will not include any untrue statement of a material fact or omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that
the Company makes no representations or warranties as to the information contained in or omitted from the Registration Statement or the
Final Prospectus Supplement (or any amendment or supplement thereto) in reliance upon and in conformity with information furnished in
writing to the Company by the Placement Agents specifically for inclusion in the Registration Statement or the Final Prospectus Supplement
(or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Placement Agents
consists of the information described as such in Section 7(b) hereof.

 

(c)            As
of the Initial Sale Time, the Pricing Disclosure Package, when taken together as a whole with the pricing information set forth in Exhibit C
hereto, does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. The preceding sentence does not apply to statements
in or omissions from the Pricing Disclosure Package based upon and in conformity with written information furnished to the Company by
the Placement Agents specifically for use therein, it being understood and agreed that the only such information furnished by or on behalf
of the Placement Agents consists of the information described as such in Section 7(b) hereof.

 

    	 	3	 

     

    

 

(d)            (i) At
the earliest time after the filing of the Registration Statement that the Company or another offering participant made a bona fide
offer (within the meaning of Rule 164(h)(2)) of the Securities and (ii) as of the Execution Time (with such date being used
as the determination date for purposes of this clause (ii)), the Company was and is an “ineligible issuer” (as defined in
Rule 405).

 

(e)            Prior
to the execution of this Agreement, the Company has not, directly or indirectly, offered or sold any of the Securities by means of any
 “prospectus” (within the meaning of the Act) or used any “prospectus” (within the meaning of the Act) in connection
with the offer or sale of the Securities, in each case other than the Registration Statement, any Preliminary Prospectus Supplement and
the Final Prospectus Supplement. The Company represents and agrees that it has not and will not make any offer relating to the Securities
that would constitute an “Issuer Free Writing Prospectus” or that would otherwise constitute a “Free Writing
Prospectus”.

 

(f)            All
statistical, demographic and market-related data included in the Registration Statement, the Pricing Disclosure Package and the Final
Prospectus Supplement are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate
in all material respects or represent the Company’s good faith estimates that are made on the basis thereof. To the extent required,
the Company has obtained the written consent for the use of such data from such sources.

 

(g)            Except
as disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, the Company maintains
disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) that have been designed to ensure
that material information relating to the Company and the Subsidiaries is made known to the Company’s principal executive officer
and principal financial officer by others within those entities; has been evaluated as of the end of the Company’s most recent
audited fiscal year and such disclosure controls and procedures are effective in all material respects to perform the functions for which
they were established. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement,
the Company and its Subsidiaries’ internal controls over financial reporting are effective and the Company and its Subsidiaries
are not aware of any material weakness in their internal controls over financial reporting. Since the date of the latest audited financial
statements included in, or incorporated by reference into, the Registration Statement, the Base Prospectus and the Final Prospectus Supplement,
there has been no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably
likely to materially affect, the Company’s internal control over financial reporting adversely.

 

(h)            The
Company has the requisite corporate power and authority to enter into and perform its obligations under each of the Transaction Documents
to which it is a party and to issue the Securities in accordance with the terms hereof and thereof. Except for approvals of the Company’s
board of directors (the “Board of Directors”) or a committee thereof as may be required in connection with any issuance
and sale of the Securities (which approvals shall be obtained prior to the date of this Agreement), the execution, delivery and performance
by the Company of each of the Transaction Documents to which it is a party and the consummation by it of the transactions contemplated
hereby and thereby have been duly and validly authorized by all necessary corporate action, and no further consent or authorization of
the Company, its Board of Directors or its shareholders is required. Each of the Transaction Documents to which the Company is a party
has been duly executed and delivered by the Company and constitutes a valid and binding obligation of the Company enforceable against
the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s
rights and remedies or by other equitable principles of general application (including any limitation of equitable remedies).

 

    	 	4	 

     

    

 

(i)            The
Securities have been duly authorized by all necessary corporate action on the part of the Company. The Securities, when issued and sold
against payment therefor in accordance with the Purchase Agreements, shall be validly issued and outstanding, fully paid and non-assessable
and free from all liens, charges, taxes, security interests, encumbrances, rights of first refusal, preemptive or similar rights and other
encumbrances with respect to the issue thereof. When paid for and issued in accordance with the Purchase Agreements, the Warrants will
constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except:
(i) as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship,
receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other
equitable principles of general application (including any limitation of equitable remedies). The Warrant Shares, when issued in accordance
with the terms of the Warrants, will be validly issued and outstanding, fully paid and non-assessable, free and clear of all liens imposed
by the Company. The Company has reserved from its duly authorized capital stock the maximum number of Shares issuable pursuant to this
Agreement and shall reserve from its duly authorized capital stock the maximum number of Warrant Shares issuable pursuant to the Warrants.

 

(j)            Except
as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, there are no
persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement
or included in the Offering, except for such rights as have been duly waived.

 

(k)            Except
as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, since the date
of the latest audited financial statements of the Company included in, or incorporated by reference into, the Registration Statement,
the Base Prospectus and the Final Prospectus Supplement: (a) neither the Company nor any of its Subsidiaries has incurred any material
liabilities or obligations, direct or contingent, or entered into any material transactions other than in the ordinary course of business,
(b) the Company has not declared or paid any dividends or made any distribution of any kind with respect to its share capital;
(c) there has not been any change in the share capital of the Company or any of its Subsidiaries (other than a change in the number
of outstanding Class A Ordinary Shares due to the issuance of shares upon the exercise of outstanding options or warrants, upon the
conversion of outstanding shares of preferred share or other convertible securities or the issuance of restricted share awards or restricted
share units under the Company’s existing share awards plan, or any new grants thereof in the ordinary course of business), (d) there
has not been any material change in the Company’s long-term or short-term debt, and (e) there has not been (1) any material
adverse change or effect or development involving a prospective material adverse change in the business, operations, properties or financial
condition of the Company and its Subsidiaries, taken as a whole (any such change or development being referred to herein as a “Material
Adverse Effect”) or (2) any change or development that could reasonably be expected to have a Material Adverse Effect on
the performance of this Agreement or the consummation of any of the transactions contemplated hereby .

 

(l)            To
the Company’s knowledge, PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft, which has expressed its opinion with
respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission
as a part of the Registration Statement, the Base Prospectus and the Final Prospectus Supplement, is (i) an independent registered
public accounting firm with respect to the Company within the meaning of the Act and as required by the Act, the Exchange Act, and the
rules of the Public Company Accounting Oversight Board (“PCAOB”), (ii) not in violation of the auditor independence
requirements of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) with respect to the Company, (iii) in
compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under
the Act and (iv) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked
and who has not requested such registration to be withdrawn.

 

    	 	5	 

     

    

 

(m)            The
financial statements filed with the Commission as a part of the Registration Statement, the Base Prospectus and the Final Prospectus Supplement,
together with the related notes and schedules thereto, comply as to form in all material respects with the applicable requirements of
the Act and the Exchange Act in effect as of the time of filing and present fairly in all material respects the financial condition of
the Company, together with its consolidated Subsidiaries, as of the dates shown and its results of operations, cash flows and changes
in stockholders’ equity for the periods shown, and such consolidated financial statements have been prepared in accordance with
International Financial Reporting Standards (the “IFRS”), as issued by the International Accounting Standards Board
and the related interpretations issued by the IFRS Interpretations Committee and applied on a consistent basis throughout the periods
covered thereby except for any normal adjustments in the Company’s financial statements. The other financial and statistical data
with respect to the Company and the Subsidiaries contained or incorporated by reference in the Registration Statement, the Pricing Disclosure
Package and the Final Prospectus Supplement are accurately and fairly presented and prepared on a basis consistent with the audited financial
statements included or incorporated by reference in the Registration Statement, the Base Prospectus and the Final Prospectus Supplement
and books and records of the Company; there are no financial statements (historical or pro forma) that are required to be included
or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement that are
not included or incorporated by reference as required. All disclosures contained or incorporated by reference in the Registration Statement,
the Pricing Disclosure Package and the Final Prospectus Supplement, if any, regarding “non-IFRS financial measures” (as such
term is defined by the rules and regulations of the Commission) comply in all material respects with Regulation G under the Exchange
Act and Item 10 of Regulation S-K under the Act, to the extent applicable. The Company and its Subsidiaries do not have any material liabilities
or obligations, direct or contingent, not described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus
Supplement which are required to be described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement.

 

(n)            Except
as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, the Company
and each of its Subsidiaries have maintained and continue to maintain a system of “internal control over financial reporting”
(as defined under Rules 13a-15 and 15d-15 under the Exchange Act) that comply with the requirements of the Exchange Act and have
been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing
similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with IFRS, including, but not limited to, internal accounting controls sufficient to provide reasonable
assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with IFRS and to maintain asset accountability;
(iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the
recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect
to any differences; and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference
in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement fairly present the information called
for in all material respects and have been prepared in accordance with the Commission’s rules and guidelines applicable thereto.

 

    	 	6	 

     

    

 

(o)            The
Company is an entity duly incorporated or otherwise organized, validly existing and in good standing as a limited liability company (naamloze
vennootschap), with the requisite power and authority to (i) own and use its properties and assets and to carry on its business
as currently conducted and (ii) enter into and perform its obligations under the Transaction Documents. The Company is not in violation
or Default (as defined below) of any of the provisions of its Organizational Documents. The Company is duly qualified to conduct business
and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or
property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case
may be, could not have or reasonably be expected to result in a Material Adverse Effect and no Action has been instituted in any such
jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

 

(p)            Each
of the Company’s “subsidiaries” (each, a “Subsidiary” and collectively, the “Subsidiaries”)
has been duly incorporated or organized, as the case may be, and is validly existing and in good standing under the laws of the jurisdiction
of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and
to conduct its business as currently conducted. Each of the Company’s Subsidiaries is duly qualified to transact business and is
in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification,
except to the extent that the failure to be so qualified or be in good standing could not have or reasonably be expected to result in
a Material Adverse Effect. All of the issued and outstanding capital stock or other equity or ownership interests of each of the Company’s
subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and are owned by the Company, directly or
through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim, except to the extent
that the existence of any such security interest, mortgage, pledge, lien, encumbrance or adverse claim would not result in a Material
Adverse Effect. The only Subsidiaries of the Company are (A) the Subsidiaries listed on Exhibit 8.1 to the Company’s most
recent Annual Report on Form 20-F filed with the Commission and (B) certain other Subsidiaries which, considered in the aggregate
as a single Subsidiary, do not constitute a “significant subsidiary” as defined in Rule 1-02 of Regulation S-X.

 

(q)            The
authorized share capital of the Company and the shares thereof issued and outstanding were in all material respects as set forth in the
Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement as of the dates reflected therein. All of the
outstanding shares of capital stock of the Company have been duly authorized and validly issued, and are fully paid and non-assessable.
Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement and this Agreement,
there are no agreements or arrangements under which the Company is obligated to register the sale of any securities under the Act. Except
as set forth in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, no shares of authorized
share capital of the Company are entitled to preemptive rights, rights of first refusal or other similar rights and there are no outstanding
debt securities and no contracts, commitments, understandings, or arrangements by which the Company is or may become bound to issue additional
shares of the capital stock of the Company or options, warrants, scrip, rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities or rights convertible into or exchangeable for, any shares of capital stock of the Company other
than those issued or granted in the ordinary course of business pursuant to the Company’s equity incentive and/or compensatory plans
or arrangements. The Class A Ordinary Shares (including the Shares and the Warrant Shares) conform in all material respects to the
description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement. Except
for customary transfer restrictions contained in agreements entered into by the Company to sell restricted securities or as set forth
in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, the Company is not a party to, and
it has no knowledge of, any agreement restricting the voting or transfer of any shares of the capital stock of the Company. Except as
set forth in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, there are no securities or
instruments containing anti-dilution or similar provisions that will be triggered by this Agreement or any of the other Transaction Documents
or the consummation of the transactions described herein or therein. The Company has filed with the Commission true and correct copies
of the Company’s Organizational Documents.

 

    	 	7	 

     

    

 

(r)            The
Class A Ordinary Shares are registered pursuant to Section 12(b) of the Exchange Act, and the Company has taken no action
designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Class A Ordinary Shares
under the Exchange Act, nor has the Company received any notification that the Commission is contemplating terminating such registration.
The Company has not received notice from Nasdaq to the effect that the Company is not in compliance with the listing or maintenance requirements
of Nasdaq. The Company is in compliance with all such listing and maintenance requirements. The Class A Ordinary Shares are eligible
for participation in the DTC book entry system and has shares on deposit at DTC for transfer electronically to third parties via DTC through
its Deposit/Withdrawal at Custodian (“DWAC”) delivery system. The Company has not received notice from DTC to the effect
that a suspension of, or restriction on, accepting additional deposits of Class A Ordinary Shares, electronic trading or book-entry
services by DTC with respect to the Class A Ordinary Shares are being imposed or is contemplated.

 

(s)            Neither
the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective Organizational Documents and neither
the Company nor any Subsidiary is in default (or, with the giving of notice or lapse of time, would be in default) (“Default”)
under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without
limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or
relating to indebtedness) to which the Company or any Subsidiary is a party or by which it or any of them may be bound, or to which any
of their respective properties or assets are subject, except for such Defaults as could not be expected, individually or in the aggregate,
to result in a Material Adverse Effect. The execution, delivery and performance by the Company of each of the Transaction Documents to
which it is a party and the consummation by the Company of the transactions contemplated hereby (including the issue and sale of the Securities)
and thereby do not and shall not (i) result in a violation of any provision of the Company’s Organizational Documents, (ii) result
in a breach or violation of any of the terms or provisions of, or constitute a Default under, or give rise to any rights of termination,
amendment, acceleration or cancellation of, any Material Agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement,
instrument or obligation to which the Company or any of its Subsidiaries is a party or is bound, (iii) create or impose a lien, charge
or encumbrance on any property or assets of the Company or any of its Subsidiaries under any agreement or any commitment to which the
Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound or to which any of their respective
properties or assets is subject, or (iv) result in a violation of any federal, state, local or foreign statute, rule, regulation,
order, judgment or decree applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any
of its Subsidiaries are bound or affected (including federal and state securities laws and regulations and the rules and regulations
of Nasdaq), except, in the case of clauses (ii), (iii) and (iv), for such conflicts, defaults, terminations, amendments, acceleration,
cancellations, liens, charges, encumbrances and violations as would not, individually or in the aggregate, be reasonably expected to have
a Material Adverse Effect. Except as specifically contemplated by this Agreement and as required under the Act and any applicable state
securities laws, the Company is not required under any federal, state, local or foreign law, rule or regulation to obtain any consent,
approval, authorization or order of, or make any filing or registration with, any court or other governmental or regulatory authority
or agency in order for it to execute, deliver or perform any of its obligations under the Transaction Documents to which it is a party,
to issue the Securities to the Investors in accordance with the terms hereof and thereof or, to the Company’s knowledge, the application
of the proceeds from the sale of the Shares as described under “Use of Proceeds” in the Registration Statement, Pricing Disclosure
Package and the Final Prospectus Supplement (other than such consents, authorizations, orders, filings or registrations as have been,
or will be, obtained or made prior to the Closing Date, including as may be required under applicable state securities or blue sky laws,
Nasdaq or the Financial Industry Regulatory Authority).

 

    	 	8	 

     

    

 

(t)            There
are no Actions pending or, to the Company’s knowledge, currently threatened against the Company or any of its Subsidiaries or their
respective assets or properties (i) other than Actions accurately described in all material respects in the Registration Statement,
the Pricing Disclosure Package and the Final Prospectus Supplement and Actions that, individually or in the aggregate, would not reasonably
be expected to have a Material Adverse Effect, or on the power or ability of the Company to perform its obligations under, or consummate
the transactions contemplated by, the Transaction Documents or (ii) that are required to be described in the Registration Statement,
the Pricing Disclosure Package and the Final Prospectus Supplement, and are not so described.

 

(u)            Neither
the Company nor any of its Subsidiaries is bound by or subject to (and none of their assets or properties is bound by or subject to) any
contract with any labor union, and, to the Company’s knowledge, no labor union has requested or has sought to represent any of the
employees of the Company or any of its Subsidiaries. There is no strike or other labor dispute involving the Company or any of its Subsidiaries
pending, or to the Company’s knowledge, threatened, that has had or would be reasonably expected to have, individually or in the
aggregate, a Material Adverse Effect, nor, to the knowledge of the Company, is there any labor organization activity involving the employees
of the Company or any of its Subsidiaries. With respect to all current and former Persons who have performed services for or on behalf
of the Company or any of its Subsidiaries, each of the Company and its Subsidiaries has complied in all material respects with all applicable
state and federal equal employment opportunity, wage and hour, compensation and other laws related to employment, including but not limited
to, overtime requirements, classification of employees and independent contractors under federal and state laws (including for tax purposes
and for purposes of determining eligibility to participate in any Employee Plan (as defined below)), hours of work, leaves of absence,
equal opportunity, sexual and other harassment, whistleblower protections, immigration, occupational health and safety, workers’
compensation, and the withholding and payment of all applicable Taxes, and there are no material arrears in the payments of wages, unemployment
insurance premiums or other similar obligations. There are no material claims, disputes, grievances, or controversies pending or, to the
knowledge of the Company, threatened involving any employee or group of employees of the Company or any of its Subsidiaries. There are
no material charges, investigations, administrative proceedings or formal complaints of (i) discrimination or retaliation (including
discrimination, harassment or retaliation based upon sex, age, marital status, race, national origin, sexual orientation, disability or
veteran status), (ii) unfair labor practices, (iii) violations of health and safety laws, (iv) workplace injuries or (v) whistleblower
retaliation against the Company or any of its Subsidiaries, in each case that (y) pertain to any current or former employee and (z) have
been threatened in writing by such employee or are pending before the Equal Employment Opportunity Commission, the National Labor Relations
Board, the U.S. Department of Labor, the U.S. Occupational Health and Safety Administration, the Workers Compensation Appeals Board, or
any other Governmental Authority.

 

    	 	9	 

     

    

 

(v)            (i) The
Company and its Subsidiaries own or have a valid license to all patents, inventions, copyrights, know how (including trade secrets and
other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade
names, domain names and other intellectual property, including any and all registrations, applications for registration, and goodwill
associated with any of the foregoing (collectively, “Intellectual Property Rights”) currently employed by them in connection
with the business, except where the failure to own, possess, license, have the right to use any of the foregoing would not reasonably
be expected to result in a Material Adverse Effect; (ii) the Intellectual Property Rights owned by the Company and its Subsidiaries
and, to the Company’s knowledge, the Intellectual Property Rights exclusively licensed to the Company and its Subsidiaries, in each
case, which are material to the conduct of the business of the Company and its Subsidiaries as described in the Registration Statement,
Pricing Disclosure Package and the Final Prospectus Supplement are valid, subsisting and enforceable, and there is no pending or, to the
Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity, scope or enforceability of
any such Intellectual Property Rights; (iii) neither the Company nor any of its Subsidiaries has received any written notice
alleging any infringement, misappropriation or other violation of Intellectual Property Rights which, individually or in the aggregate,
if the subject of an unfavorable decision, ruling or finding, would be reasonably expected to have a Material Adverse Effect; (iv) all
Intellectual Property Rights owned or purported to be owned by the Company or its Subsidiaries is owned solely by the Company or its Subsidiaries
and is owned free and clear of all liens, encumbrances, defects and other restrictions except for liens, encumbrances, defects and restrictions
as would not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect; (v) to the Company’s
knowledge, no third party is infringing, misappropriating or otherwise violating, or has infringed, misappropriated or otherwise violated,
any Intellectual Property Rights owned by the Company, except to the extent that the infringement, misappropriation or violation, would
not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect; (vi) to the Company’s
knowledge, neither the Company nor any of its Subsidiaries infringes, misappropriates or otherwise violates, or has infringed, misappropriated
or otherwise violated, any Intellectual Property Rights of a third party that would, individually or in the aggregate, be reasonably expected
to have a Material Adverse Effect; (vii) all employees or contractors engaged in the development of Intellectual Property Rights
on behalf of the Company or any Subsidiary have executed an invention assignment agreement whereby such employees or contractors presently
assign all of their right, title and interest in and to such Intellectual Property Rights to the Company or the applicable Subsidiary,
and to the Company’s knowledge no such agreement has been breached or violated, or Intellectual Property Rights have been assigned
to the Company by applicable law; and (viii) the Company and its Subsidiaries use, and have used, commercially reasonable efforts
to appropriately maintain all information intended to be maintained as a trade secret. The Intellectual Property owned by the Company
has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. The Company and its Subsidiaries
have materially complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or
any Subsidiary, and all such material agreements are, to the Company’s knowledge, in full force and effect. To the Company’s
knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual Property. The Company
and its Subsidiaries have taken commercially reasonable steps to protect, maintain and safeguard Intellectual Property owned by the Company,
including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments
with their employees, and, to the Company’s knowledge, no employee of the Company is in or has been in violation of any term of
any such agreement except as would not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect.

 

(w)            The
Company and its Subsidiaries possess all material certificates, authorizations and permits issued by the appropriate federal, state or
foreign regulatory authorities necessary to conduct their respective businesses, except where the failure to possess such certificates,
authorizations or permits would not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect;
and neither the Company nor any of its Subsidiaries has received any notice of proceedings relating to the revocation or modification
of any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling
or finding, would reasonably be expected to have a Material Adverse Effect, except, in each case, as described in the Registration Statement,
the Pricing Disclosure Package and the Final Prospectus Supplement. This Section 2(w) does not relate to environmental matters,
such items being the subject of Section 2(ee).

 

    	 	10	 

     

    

 

(x)            The
Company and each of its Subsidiaries has good and marketable title in fee simple to all real property and good and marketable title to
all personal property owned by them which is material to the business of the Company and its Subsidiaries, in each case free and clear
of all liens, encumbrances and defects except such as do not materially affect the value of such property and do not interfere with the
use made and proposed to be made of such property by the Company and its Subsidiaries; and any real property and buildings held under
lease by the Company and its Subsidiaries are held by it under valid, subsisting and enforceable leases with such exceptions as are not
material and do not interfere in any material respect with the use made and proposed to be made of such property and buildings by the
Company and its Subsidiaries.

  

(y)            Each
of the Company and its Subsidiaries has (a) filed all material foreign, federal, state and local Tax Returns required to be filed
with taxing authorities prior to the date hereof or has duly obtained extensions of time for the filing thereof and (b) paid all
material Taxes shown as due and payable on such returns that were filed and has paid all material Taxes imposed on or assessed against
the Company or such respective Subsidiary. The provisions for Taxes payable, if any, shown on the financial statements included or incorporated
by reference in the Registration Statement, the Base Prospectus and the Final Prospectus Supplement are sufficient for all accrued and
unpaid Taxes, whether or not disputed, and for all periods to and including the dates of such consolidated financial statements. To the
Company’s knowledge, no issues have been raised (and are currently pending) by any taxing authority in connection with any of the
Tax Returns or Taxes asserted as due from the Company or its Subsidiaries, and no waivers of statutes of limitation with respect to the
returns or collection of Taxes have been given by or requested from the Company or its Subsidiaries that would be reasonably likely to
result in a Material Adverse Effect.

 

(z)            To
the Company’s knowledge, based on the current and anticipated value of its assets and the nature and composition of its income and
assets, and subject to the qualifications set forth in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus
Supplement, the Company was not “passive foreign investment company” within the meaning of Section 1297 of the Code for
the taxable year ending December 31, 2021.

 

(aa)          The Company
is not, and as a result of the consummation of the transactions contemplated by the Transaction Documents and the application of the proceeds
from the sale of the Securities as will be set forth in the Registration Statement (and any post-effective amendment thereto), the Pricing
Disclosure Package and the Final Prospectus Supplement will not be an “investment company” within the meaning of the Investment
Company Act of 1940, as amended.

 

(bb)          The Company
and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts
as, in the Company’s reasonable judgment, are prudent and customary in the businesses in which the Company and the Subsidiaries
are engaged, including, but not limited to, directors and officers insurance coverage. The Company has no reason to believe that it will
not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers
as may be necessary to continue its business at a cost that would not, individually or in the aggregate, be reasonably expected to have
a Material Adverse Effect on the Company.

 

(cc)          Neither the
Company nor any of its officers, directors or Affiliates has, and, to the knowledge of the Company, no Person acting on their behalf has,
(i) taken, directly or indirectly, any action designed or intended to cause or to result in the stabilization or manipulation of
the price of any security of the Company, including any “reference security” (as defined in Rule 100 of Regulation M
under the Exchange Act), or which caused or resulted in, or which would in the future reasonably be expected to cause or result in, the
stabilization or manipulation of the price of any security of the Company, in each case to facilitate the sale or resale of any of the
Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid
or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company. Neither the Company
nor any of its officers, directors or Affiliates will during the term of this Agreement, and, to the knowledge of the Company, no Person
acting on their behalf will during the term of this Agreement, take any of the actions referred to in the immediately preceding sentence.

 

    	 	11	 

     

    

 

(dd)          Except as disclosed
in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, none of the officers or directors of
the Company and, to the knowledge of the Company, none of the Company’s shareholders, the officers or directors of any shareholder
of the Company, or any family member or Affiliate of any of the foregoing, has either directly or indirectly any interest in, or is a
party to, any transaction that is required to be disclosed by the Company as a related party transaction pursuant to Item 404 of Regulation
S-K promulgated under the Act.

 

(ee)          Except as set
forth in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, the Company and its Subsidiaries
(i) are in compliance with all applicable federal, state, local and foreign laws relating to pollution or protection of human health
(to the extent relating to exposure to Hazardous Materials, defined below) and safety, the environment (including, without limitation,
ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations
relating to the release of hazardous or toxic substances or wastes, pollutants or contaminants that are subject to regulation by any governmental
authority (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution, use, treatment, storage,
disposal, transport or handling of Hazardous Materials (“Environmental Laws”); (ii) have received all permits,
authorizations or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and
(iii) are in compliance with all terms and conditions of any such permit, authorization or approval, where in each clause (i), (ii) and
(iii), the failure to so comply would be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect. The
Company and its Subsidiaries have not received notice of any pending or threatened liability under any Environmental Law, except where
such notice, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.

 

(ff)          Except as set
forth in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, neither the Company nor any of
its Subsidiaries is a party to an “employee benefit plan,” as defined in Section 3(3) of the Employee Retirement
Income Security Act of 1974, as amended (“ERISA”), which: (i) is subject to Title IV of ERISA and (ii) is
or was at any time maintained, administered or contributed to by the Company or any of its ERISA Affiliates (as defined hereafter). Each
plan is referred to herein as an “Employee Plan.” An “ERISA Affiliate” of any Person means any other
Person which, together with that Person, could be treated as a single employer under Section 414(b), (c), (m) or (o) of
Code. Each Employee Plan has been maintained in material compliance with its terms and the requirements of applicable law. Except as disclosed
in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, there is no liability in respect of
post-retirement health and medical benefits for retired employees of the Company or any of its ERISA Affiliates, other than medical benefits
required to be continued under applicable law. No “prohibited transaction”(as defined in either Section 406 of ERISA
or Section 4975 of the Code) has occurred with respect to any Employee Plan; and each Employee Plan that is intended to be qualified
under Section 401(a) of the Code is so qualified, and nothing has occurred, whether by action or by failure to act, which could
cause the loss of such qualification, except where such occurrence or failure to qualify would not, individually or in the aggregate,
be reasonably expected to have a Material Adverse Effect. With respect to each Employee Plan, no Actions (other than routine claims for
benefits in the ordinary course of business) are pending or, to the knowledge of the Company, threatened, and, to the knowledge of the
Company, no facts or circumstances exist that would reasonably be expected to give rise to any such Actions. No Employee Plan is currently
under investigation or audit by any Governmental Authority and, to the knowledge of the Company, no such investigation or audit is contemplated
or under consideration. Each Employee Plan that is a “nonqualified deferred compensation plan” subject to Section 409A
of the Code has been maintained and administered in all material respects in accordance with its terms and in operational and documentary
compliance with Section 409A of the Code and all regulations and other applicable regulatory guidance (including notices and rulings)
thereunder.

 

    	 	12	 

     

    

 

(gg)          Except for
fees payable by the Company to the Placement Agents, no brokerage or finder’s fees or commissions are or will be payable by the
Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect
to the transactions contemplated by the Transaction Documents.

 

(hh)          The business
of the Company and the Subsidiaries is presently being conducted in compliance with all applicable federal, state, local and foreign governmental
laws, rules, regulations and ordinances, except for such non-compliance which, individually or in the aggregate, would not be reasonably
expected to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is in violation of any judgment, decree or
order or any statute, ordinance, rule or regulation of any Governmental Authority applicable to the Company or any of its Subsidiaries,
and neither the Company nor any of its Subsidiaries will conduct its business in violation of any of the foregoing, except in all cases
for any such violations which could not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect. There
are no statutes, laws, rules, regulations or ordinances of any Governmental Authority, self-regulatory organization or body that are applicable
to the Company or any of its Subsidiaries or to their respective businesses, assets or properties that are required to be described in
the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement that are not described therein as required.

 

(ii)            Neither
the Company nor any of its Subsidiaries nor any director or officer, nor, to the knowledge of the Company, any employee, agent, representative
or Affiliate or other Person acting on behalf of the Company or any of its Subsidiaries has, in the course of its actions for, or on behalf
of, the Company or any of its Subsidiaries (i) used any corporate funds for any unlawful contribution, gift, entertainment or other
unlawful expenses relating to political activity; (ii) taken any action in furtherance of an offer, payment, promise to pay,
or authorization or approval of the payment or giving of money, property, gifts or anything else of value, directly or indirectly, to
any “government official” (including any officer or employee of a government or government-owned or controlled entity or of
a public international organization, or any Person acting in an official capacity for or on behalf of any of the foregoing, or any political
party or party official of any federal, state or foreign office or candidate for any federal, state or foreign political office) to improperly
influence official action or secure an improper advantage (to the extent acting on behalf of or providing services to the Company); (iii) violated
or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), the
UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, authorized, requested,
or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit.
The Company and its Subsidiaries and, to the knowledge of the Company, the Company’s Affiliates have conducted their businesses
in compliance with the FCPA, any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public
Officials in International Business Transactions, signed December 17, 1997, the U.K. Bribery Act 2010 and other applicable anti-corruption,
anti-money laundering and anti-bribery laws, and have instituted and maintain policies and procedures designed to promote and achieve
compliance with such laws and with the representation and warranty contained herein.

 

    	 	13	 

     

    

 

(jj)          The operations
of the Company are and have been conducted at all times in material compliance with all applicable financial recordkeeping and reporting
requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, and the applicable anti-money
laundering statutes, including but not limited to, applicable federal, state, international, foreign or other laws, regulations or government
guidance regarding anti-money laundering, including, without limitation, Title 18 U.S. Code Section 1956 and 1957, the Patriot Act,
the Bank Secrecy Act, and international anti-money laundering principles or procedures by an intergovernmental group or organization,
such as the Financial Action Task Force on Money Laundering, of which the United States is a member and with which designation the United
States representative to the group or organization continues to concur, all as amended, and any Executive order, directive, or regulation
pursuant to the authority of any of the foregoing, or any orders or licenses issued thereunder, of jurisdictions where the Company conducts
business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered
or enforced by any governmental agency (collectively, the “Money Laundering Laws”), and no action, suit or proceeding
by or before any court or governmental agency, authority or body or any arbitrator involving the Company or its Subsidiaries with respect
to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

 

(kk)          Neither the
Company nor any of its Subsidiaries, nor any director or officer thereof, nor, to the Company’s knowledge, any employee, agent,
Affiliate or representative of the Company, is a Person that is, or is majority owned or controlled by a Person that is (i) named
on the Specially Designated Nationals and Blocked Persons List, the Foreign Sanctions Evaders List, the Sectoral Sanctions Identification
List, or any other similar list of sanctioned persons (collectively, “Sanction Lists”) administered by the U.S. Treasury
Department’s Office of Foreign Assets Control (“OFAC”), or any similar list of sanctioned persons administered
by the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty’s Treasury of the United Kingdom,
any individual European Union member state, including the United Kingdom or other relevant sanctions authority, nor (ii) located,
organized or resident of the Crimea Region of Ukraine, the so-called Donetsk People’s Republic, the so-called Luhansk People’s
Republic, Cuba, Iran, North Korea, Sudan or Syria, or any other country (each a “Sanction Country” and collectively,
 “Sanction Countries”) or territory embargoed or subject to substantial trade restrictions by the United States, the
European Union or any individual European Union member state, including the United Kingdom. Neither the Company nor any of its Subsidiaries
will, directly or indirectly, use the proceeds from the sale of Securities under the Transaction Documents, or lend, contribute or otherwise
make available such proceeds to any Subsidiary, joint venture partner or other Person (a) to fund or facilitate any activities or
business of or with any Person or any Sanctioned Country, or (b) in any other manner that will result in a violation of Sanction
Lists by any Person (including any Person participating in the Offering, whether as underwriter, advisor, investor or otherwise). For
the past five (5) years, neither the Company nor any of its Subsidiaries have knowingly engaged in, or are now knowingly engaged
in, any dealings or transactions with any Person that at the time of the dealing or transaction is or was the subject of Sanction Lists
or a Sanction Country.

 

(ll)          There is and
has been no failure on the part of the Company or any of the Company’s directors or officers, in their capacities as such, to comply
in all material respects with any applicable provision of the Sarbanes-Oxley Act and the rules and regulations promulgated in connection
therewith.

 

    	 	14	 

     

    

 

(mm)          Except as would
not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect, the Company’s and its Subsidiaries’
information technology (i) assets and equipment, (ii) computers, (iii) systems, (iv) networks, (v) hardware,
(vi) software, (vii) websites, (viii) applications, and (ix) databases (collectively, “IT Systems”)
operate and perform as required in connection with the operation of the business of the Company as currently conducted, free and clear
of all bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. Except as disclosed in the Registration Statement,
the Pricing Disclosure Package and the Final Prospectus Supplement, and except as would not reasonably be expected to, individually or
in the aggregate, have a Material Adverse Effect, the Company and its Subsidiaries have implemented and maintained commercially reasonable
physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their confidential information
and the integrity, continuous operation, redundancy and security of all IT Systems and data, including all Personal Data (defined below)
and all other sensitive, confidential or regulated data controlled by the Company and its Subsidiaries in connection with their businesses
(“Confidential Data”). “Personal Data” means, to the extent applicable to the Company’s business,
any information which would qualify as (i) “personally identifying information” under the Federal Trade Commission Act,
as amended; (ii) “personal data” as defined by the European Union General Data Protection Regulation (“GDPR”)
(EU 2016/679); (iii) “personal information” as defined by the California Consumer Privacy Act (“CCPA”)
or (iv) any other term of similar import as defined under any Privacy Law. “Privacy Laws” means applicable state and
federal data privacy and security laws and regulations, including, to the extent applicable, the CCPA and the GDPR. Except as disclosed
in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, and except as would not reasonably
be expected to, individually or in the aggregate, have a Material Adverse Effect, to the Company’s knowledge, there have been no
breaches, violations, outages or unauthorized uses of or accesses to any Personal Data controlled by the Company and its Subsidiaries,
except for those that have been remedied without cost or liability or the duty to notify any other person, nor any incidents under internal
review or investigations relating to the same. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the
Final Prospectus Supplement, and except as would not reasonably be expected to, individually or in the aggregate, to have a Material Adverse
Effect, the Company and its Subsidiaries are in compliance with all Privacy Laws, applicable judgments, orders or rules of any court,
arbitrator or governmental or regulatory authority, external policies and contractual obligations, in each case to the extent relating
to the privacy and security of IT Systems, Confidential Data, and Personal Data controlled by the Company and its Subsidiaries in connection
with their businesses and to the protection of such IT Systems, Confidential Data, and Personal Data from unauthorized use, access, misappropriation
or modification. Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement,
and except as would not reasonably be expected to, individually or in the aggregate, to have a Material Adverse Effect, neither the Company
nor any of its Subsidiaries: (i) has received written notice of any actual or potential violation of any of the Privacy Laws, or
has any knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently
conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any violation of
any Privacy Law; or (iii) is a party to any order or decree that imposes any obligation or liability under any Privacy Law.

 

(nn)          Except as would
not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect, each stock option granted by the Company
was granted (i) in accordance with the terms of the applicable stock option plan of the Company and (ii) with an exercise price
at least equal to the fair market value of the Class A Ordinary Shares on the date such stock option would be considered granted
under IFRS and applicable law. No stock option granted under the Company’s stock option plan has been backdated. The Company has
not knowingly granted, and there is no and has been no policy or practice of the Company to knowingly grant, stock options prior to, or
otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding
the Company or its Subsidiaries or their financial results or prospects.

 

    	 	15	 

     

    

 

(oo)            Except
as set forth in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, neither the Company nor
any Subsidiary of the Company is a party to any contract, agreement or plan, a copy of which would be required to be filed with the Commission
as an exhibit to an annual report on Form 20-F (collectively, “Material Agreements”). Each of the Material Agreements
described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement conform in all material respects
to the descriptions thereof contained or incorporated by reference therein. Except as set forth in the Registration Statement, the Pricing
Disclosure Package and the Final Prospectus Supplement, the Company and each of its Subsidiaries have performed in all material respects
all the obligations then required to be performed by them under the Material Agreements, have received no notice of default or an event
of default by the Company or any of its Subsidiaries thereunder and are not aware of any basis for the assertion thereof, and neither
the Company or any of its Subsidiaries nor, to the knowledge of the Company, any other contracting party thereto are in default under
any Material Agreement now in effect, the result of which would be reasonably expected to have a Material Adverse Effect. Each of the
Material Agreements is in full force and effect, and constitutes a legal, valid and binding obligation enforceable in accordance with
its terms against the Company and/or any of its Subsidiaries and, to the knowledge of the Company, each other contracting party thereto,
except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship,
receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other
equitable principles of general application.

 

(pp)          Since December 31,
2021, the Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to any Bankruptcy
Law, nor does the Company have any knowledge that its creditors intend to initiate involuntary bankruptcy, insolvency, reorganization
or liquidation proceedings or other proceedings for relief under any Bankruptcy Law. The Company is financially solvent and is generally
able to pay its debts as they become due.

 

(qq)          Neither the
Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or
unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any
Subsidiary (including the notes thereto) in conformity with IFRS and are not disclosed in Registration Statement, the Pricing Disclosure
Package and the Final Prospectus Supplement, other than those incurred in the ordinary course of the Company’s or its Subsidiaries
respective businesses since the date of the latest audited financial statements of the Company included or incorporated by reference in
the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement and which, individually or in the aggregate,
would not reasonably be expected to have a Material Adverse Effect.

 

(rr)          None of the
Company or any of its Affiliates, nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any security
or solicited any offers to buy any security, under circumstances that would require registration of the offer, issuance and sale by the
Company to the Investor of any of the Securities under the Act, whether through integration with prior offerings or otherwise. None of
the Company, its Subsidiaries, their Affiliates nor any Person acting on their behalf will take any action or steps referred to in the
preceding sentence that would require registration of the offer, issuance and sale by the Company to the Investors of any of the Securities
under the Act or cause the Offering to be integrated with any other offering of securities of the Company.

 

(ss)          Except as provided
by laws or statutes generally applicable to transactions of the type described in this Agreement, neither the Company nor any of its respective
properties, assets or revenues has any right of immunity under the laws of the Netherlands, New York or United States law, from any legal
action, suit or proceeding, from the giving of any relief in any such legal action, suit or proceeding, from set-off or counterclaim,
from the jurisdiction of any Dutch, New York or United States federal court, from service of process, attachment upon or prior judgment,
or attachment in aid of execution of judgment, or from execution of a judgment, or other legal process or proceeding for the giving of
any relief or for the enforcement of a judgment, in any such court, with respect to its obligations, liabilities or any other matter under
or arising out of or in connection with this Agreement. To the extent that the Company or any of its respective properties, assets or
revenues may have or may hereafter become entitled to any such right of immunity in any such court in which proceedings may at any time
be commenced, the Company waives or will waive such right to the extent permitted by law and has consented to such relief and enforcement
as provided in Section 10(b) of this Agreement.

 

    	 	16	 

     

    

 

(tt)            [Reserved].

 

(uu)          No stamp, issue,
registration, documentary, transfer or other similar taxes and duties, including interest and penalties, are payable on or in connection
with the issuance and sale of the Securities by the Company or the execution and delivery of this Agreement.

 

(vv)          The statements
in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement under the headings “Taxation”
to the extent such statements are statements of, or conclusions with respect to, U.S., Dutch and German tax law are correct in all material
respects.

 

(ww)          Except as disclosed
in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, (i) under current laws and regulations
of the Netherlands or Germany and any political subdivision thereof, all dividends and other distributions declared and payable on the
Securities may be paid by the Company to the holder thereof and all amounts payable to the Placement Agents pursuant this Agreement may
be paid by the Company to the Placement Agents, in United States dollars or euros that may be converted into foreign currency and freely
transferred out of euros and (ii) all such payments made to holders thereof or therein or the Placement Agents who are non-residents
of the Netherlands, Germany or the United States will not be subject to income, withholding or other taxes under laws and regulations
of the Netherlands, Germany or the United States or any political subdivision or taxing authority of either the Netherlands, Germany or
the United States (the “Relevant Tax Jurisdiction”) and will otherwise be free and clear of any other tax, duty, withholding
or deduction in the Relevant Tax Jurisdiction and without the necessity of obtaining any governmental authorization in the Relevant Tax
Jurisdiction.

 

(xx)            All
payments made by the Company to the Placement Agents under this Agreement will not be subject to withholding taxes under the laws and
regulations of the Relevant Tax Jurisdiction.

 

(yy)          Subject to
the qualifications and limitations set forth in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement,
the Company is, as of the date hereof, a resident of Germany for purposes of the 2012 Convention between the Federal Republic of Germany
and the Kingdom of the Netherlands for the avoidance of double taxation and the prevention of fiscal evasion with respect to taxes on
income and the Company’s Subsidiary Lilium GmbH is and has at all times been resident for tax purposes only in its jurisdiction
of incorporation and is and has not been treated as resident in any other jurisdiction for any tax purpose (including any double tax treaty).

 

(zz)           There are no
transactions, arrangements and other relationships between and/or among the Company, and/or, to the knowledge of the Company, any of its
affiliates and any unconsolidated entity, including, but not limited to, any structural finance, special purpose or limited purpose entity
(each, an “Off-Balance Sheet Transaction”) that could reasonably be expected to affect materially the Company’s
liquidity or the availability of or requirements for its capital resources, including those Off Balance Sheet Transactions described in
the Commission’s Statement about Management’s Discussion and Analysis of Financial Conditions and Results of Operations (Release
Nos. 33-8056; 34-45321; FR-61), and are required to be described in the Pricing Disclosure Package and the Final Prospectus Supplement,
which have not been described as required.

 

(aaa)          The section
entitled “Critical Accounting Policies” incorporated by reference in the Registration Statement, the Pricing Disclosure Package
and the Final Prospectus Supplement accurately describes in all material respects (i) the accounting policies that the Company believes
are the most important in the portrayal of the Company’s financial condition and results of operations and that require management’s
most difficult, subjective or complex judgments (“Critical Accounting Policies”); (ii) the judgments and uncertainties
affecting the application of Critical Accounting Policies; and (iii) the likelihood that materially different amounts would be reported
under different conditions or using different assumptions, and an explanation thereof.

 

    	 	17	 

     

    

 

(bbb)        Except as
disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, the Company is not a party
to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed
by any governmental authority.

 

(ccc)        Any certificate
signed by any officer of the Company and delivered to the Placement Agents or counsel for the Placement Agents in connection with the
offering of the Securities shall be deemed a representation and warranty by the Company, as to matters specifically covered thereby, to
the Placement Agents, as applicable.

 

3.            Certain
Covenants of the Company. The Company hereby agrees with each Placement Agent:

 

(a)            During
the Prospectus Delivery Period, before using or filing any amendment or supplement to the Registration Statement or the Final Prospectus
Supplement (in each case, other than due to the filing of an Incorporated Document), to furnish to the Placement Agents, upon such party’s
written request, a copy of each such amendment or supplement within a reasonable period of time before filing with the Commission or using
any such amendment or supplement and the Company will not use or file any such proposed amendment or supplement to which any of the Placement
Agents reasonably objects, unless the Company’s legal counsel has advised the Company that use or filing of such document is required
by law.

 

(b)            To
file the Final Prospectus Supplement within the time period required by Rule 424(b) under the Act (without reference to Rule 424(b)(8))
and to provide copies of any Preliminary Prospectus Supplement, the Final Prospectus Supplement, any other amendments or supplements to
the Final Prospectus Supplement and (to the extent not previously delivered or filed on the Commission’s Electronic Data Gathering,
Analysis and Retrieval system or any successor system thereto (collectively, “EDGAR”)) to the Placement Agents, upon
written request of such party, via e-mail in “.pdf” format on such filing date to an e-mail account designated by the Placement
Agents and, at the relevant party’s written request, to also furnish copies of any Preliminary Prospectus Supplement, the Final
Prospectus Supplement, any other amendments or supplements to the Final Prospectus Supplement to each exchange or market on which sales
were effected as may be required by the rules or regulations of such exchange or market. To file timely all reports and any definitive
proxy or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14 or
15(d) of the Exchange Act during the Prospectus Delivery Period, and during such same period to advise the Placement Agents promptly
after the Company receives notice thereof, (i) when the Final Prospectus Supplement, and any amendment or supplement thereto, shall
have been filed (if required) with the Commission pursuant to Rule 424(b) under the Act; (ii) when, prior to the termination
of the Offering, any amendment to the Registration Statement has been filed or has become effective (iii) of the issuance by the
Commission of any stop order or any order preventing or suspending the use of any prospectus relating to the Shares or the initiation
or threatening of any proceeding for that purpose, pursuant to Section 8A of the Act; (iv) of any objection by the Commission
to the use of Form F-3 by the Company pursuant to Rule 401(g)(2) under the Act; (v) of the suspension of the
qualification of the Shares for offering or sale in any jurisdiction or of the initiation or threatening in writing of any proceeding
for any such purpose; (vi) of any request by the Commission for the amendment of the Registration Statement or the amendment
or supplementation of the Final Prospectus Supplement (in each case including any documents incorporated by reference therein) or for
additional information; (vii) of the occurrence of any event, as a result of which the Final Prospectus Supplement as then amended
or supplemented includes any untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary
in order to make the statements therein, in the light of the circumstances existing when the Final Prospectus Supplement is delivered
to a purchaser, not misleading; and (viii) of the receipt by the Company of any notice of objection of the Commission to the
use of the Registration Statement or any post-effective amendment thereto; and in the event of the issuance of any such stop order
or of any such order preventing or suspending the use of any such prospectus or suspending any such qualification, or of any notice of
objection pursuant to Rule 401(g)(2) under the Act, to use promptly its commercially reasonable efforts to obtain its withdrawal.

 

    	 	18	 

     

    

 

(c)            Upon
request, the Company will furnish to the Placement Agents and counsel for the Placement Agents, without charge, two signed copies of the
Registration Statement (including exhibits thereto) and, during the Prospectus Delivery Period, as many copies of each Base Prospectus,
the Final Prospectus Supplement and any amendment or supplement thereto as the Placement Agents may reasonably request; provided,
however, that the Company shall have no obligation to provide the Placement Agents with any document filed on EDGAR or included on the
Company’s internet website.

 

(d)            Upon
request, during the Prospectus Delivery Period, to furnish or make available to the Placement Agents (i) copies of any reports or
other communications which the Company shall send to its shareholders or shall from time to time publish or publicly disseminate and (ii) copies
of all annual reports and reports of Foreign Private Issuers filed with the Commission on Forms 20-F and 6-K, respectively, or such other
similar form as may be designated by the Commission, and to furnish to the Placement Agents, as applicable, from time to time such other
information as the Placement Agents may reasonably request regarding the Company or its subsidiaries, in each case as soon as such reports,
communications, documents or information becomes available or promptly upon the request of the Placement Agents, as applicable; provided,
however, that the Company shall have no obligation to provide the Placement Agents with any document filed on EDGAR or included on the
Company’s internet website.

 

(e)            If,
at any time during the Prospectus Delivery Period, any event shall occur or condition shall exist as a result of which it is necessary
in the reasonable opinion of counsel for the Placement Agents and counsel for the Company, to further amend or supplement the Final Prospectus
Supplement as then amended or supplemented in order that the Final Prospectus Supplement will not include an untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading,
in light of the circumstances existing at the time the Final Prospectus Supplement is delivered to a purchaser, or if it shall be necessary,
in the reasonable opinion of such counsel, to amend or supplement the Registration Statement or the Final Prospectus Supplement in order
to comply with the requirements of the Act, the Company will, subject to Section 1(a) above, promptly prepare and file with
the Commission such amendment or supplement, whether by filing documents pursuant to the Act, the Exchange Act or otherwise, as may be
necessary to correct such untrue statement or omission or to make the Registration Statement, the Final Prospectus Supplement or comply
with such requirements.

 

(f)            To
generally make available to its security holders and the Placement Agents as soon as reasonably practicable, but not later than 9 months
after the first day of the fiscal quarter following the period referred to below, an earnings statement (in form complying with the provisions
of Section 11(a) under the Act and Rule 158 of the Commission promulgated thereunder) covering a period of at least twelve
months beginning after the “effective date” (as defined in such Rule 158) of the Registration Statement.

 

    	 	19	 

     

    

 

(g)            To
apply the net proceeds from the sale of the Securities in the manner described in the Final Prospectus Supplement under the caption “Use
of Proceeds.”

 

(h)            Not
to, and to cause its subsidiaries not to, take, directly or indirectly, any action designed to cause or result in, or that constitutes
or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of the Shares; provided that nothing herein shall prevent the Company from filing or submitting reports under
the Exchange Act or issuing press releases in the ordinary course of business.

 

(i)            All
payments to be made by the Company to the Placement Agents hereunder shall be made without withholding or deduction for or on account
of any present or future taxes, duties or governmental charges whatsoever imposed, levied, collected, withheld or assessed by a Relevant
Tax Jurisdiction, unless the Company is compelled by law to deduct or withhold such taxes, duties or charges. In that event, except for
any such tax imposed by reason of a Placement Agent’s (i) having some present or former connection with the Relevant Tax Jurisdiction
other than its participation as Placement Agent hereunder or (ii) failure to provide, upon reasonable request from the Company, a
certificate, form or other applicable document that it is able to provide to reduce or eliminate such tax, the Company shall pay such
additional amounts as may be necessary in order that the net amounts received after such withholding or deduction shall equal the amounts
that would have been received if no withholding or deduction had been made.

 

4.            Conditions
of Placement Agents’ Obligations.

 

The obligations of the Placement Agents hereunder
are subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions,
except as otherwise disclosed to and acknowledged and waived by the Placement Agents:

 

(a)            The
Final Prospectus Supplement shall have been filed with the Commission pursuant to Rule 424(b) at or before 5:30 p.m., New York
City time, on the second full business day after the date of this Agreement (or such earlier time as may be required under the Act).

 

(b)            The
respective representations and warranties of the Company contained herein shall be true and correct on the date hereof and on and as of
the Closing Date and the statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall
be true and correct on and as of the Closing Date.

 

(c)            On
the date hereof and as of the Closing Date: (i) no stop order suspending the effectiveness of the Registration Statement shall have
been issued under the Act and no proceedings initiated under Section 8(d) or 8(e) of the Act for that purpose or pursuant
to Section 8A of the Act shall be pending or, to the knowledge of the Company, threatened by the Commission, and (ii) any request
for additional information on the part of the Commission (to be included in the Registration Statement, the Pricing Disclosure Package
or the Final Prospectus Supplement or otherwise) shall have been complied with to the reasonable satisfaction of the Placement Agents.

 

(d)            Subject
to the execution and delivery of this Agreement and as of the Closing Date, no event or condition of a type described in Section 2(k) hereof
shall have occurred or shall exist that is material and adverse to the Company (without duplication of any material adverse effect qualifier
contained therein), which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement
thereto) and the Final Prospectus Supplement (excluding any amendment or supplement thereto) and the effect of which in the judgment of
the Placement Agents makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing
Date on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Final Prospectus Supplement.

 

    	 	20	 

     

    

  

(e)            The
Company shall have furnished to the Placement Agents a certificate of the Company, signed by the Chief Executive Officer, President or
Chief Financial Officer of the Company, dated the Closing Date, to the effect that he or she has carefully examined the Registration Statement,
the Pricing Disclosure Package and the Final Prospectus Supplement, any supplements or amendments thereto and this Agreement and that,
to the knowledge of such officer and subject to the execution and delivery of this Agreement and as of the Closing Date:

 

1)            the
representations and warranties of the Company in this Agreement are true and correct on and as of the Closing Date with the same effect
as if made on such date, except for those representations and warranties that speak solely as of a specific date and were true and correct
as of such date, and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or
satisfied at or prior to the Closing Date;

 

2)            no
stop order suspending the effectiveness of the Registration Statement or notice by the Commission objecting to its use has been issued
and no proceedings for that purpose have been instituted or, to the Company’s knowledge, threatened; and

 

3)            confirming
to the effect set forth in paragraph (d) above.

 

(f)            The
Company shall have requested and caused PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft to have furnished to the Placement
Agents, on the date of this Agreement and at the Closing Date, comfort letters, dated respectively as of the date of this Agreement and
the Closing Date in form and substance reasonably satisfactory to the Placement Agents, including confirmation that (i) they are
an independent registered public accounting firm with respect to the Company within the meaning of the Act and the applicable rules and
regulations thereunder adopted by the Commission and the Public Company Accounting Oversight Board (United States) (“PCAOB”)
and (ii) they have performed an audit of the consolidated financial statements of the Company as of December 31, 2021 and 2020,
and for each of the three years in the period ended December 31, 2021, and the related financial statement schedule.

 

(g)            The
Company shall have requested and caused to be delivered an opinion, and, if not covered in such opinion, a negative assurance letter of
Freshfields Bruckhaus Deringer LLP, counsel for the Company, addressed to each of the Placement Agents and dated the Closing Date, in
form and substance reasonably satisfactory to the Placement Agents.

 

(h)

 

(i)            The
Placement Agents shall have received from Latham & Watkins LLP, counsel for the Placement Agents, such letter and opinion or
opinions dated the Closing Date, addressed to each of the Placement Agents and addressing such matters as the Placement Agents may reasonably
require, and the Company shall have furnished to such counsel such documents as they may reasonably request for the purpose of enabling
them to pass upon such matters.

 

(j)            Subsequent
to the earlier of (i) the Initial Sale Time and (ii) the execution and delivery of this Agreement, (A) no downgrading shall
have occurred in the rating accorded any debt securities, convertible securities or preferred stock issued, or guaranteed by, the Company
or any of its subsidiaries by any “nationally recognized statistical rating organization,” as such term is defined under Section 3(a)(62)
under the Exchange Act and (B) no such organization shall have publicly announced that it has under surveillance or review, or has
changed its outlook with respect to, its rating of any such debt securities or preferred stock issued or guaranteed by the Company or
any of its Subsidiaries (other than an announcement with positive implications of a possible upgrading).

 

    	 	21	 

     

    

 

(k)            The
Company shall have submitted to Nasdaq a Notification of Listing of Additional Shares with respect to the Shares and the Warrant Shares
and Nasdaq shall not have objected thereto.

 

(l)             Prior
to the Closing Date, the Company shall have furnished to the Placement Agents (1) a certificate of the chief financial officer with
respect to certain financial data contained in or incorporated by reference into the Registration Statement, the Pricing Disclosure Package
and the Final Prospectus Supplement, in form and substance reasonably satisfactory to the Placement Agents and (2) such further information,
certificates and documents as the Placement Agents may reasonably request.

 

The documents required to be delivered by this
Section 4 shall be delivered by email exchange on the Closing Date.

 

5.            Effectiveness
of Agreement. This Agreement shall become effective as of the date first written above.

 

6.            Termination.
This Agreement shall be subject to termination in the absolute discretion of the Placement Agents, by notice given to the Company if after
the execution and delivery of this Agreement and on or prior to the Closing Date (i) trading in the Company’s Class A
Ordinary Shares shall have been suspended by the Commission or Nasdaq or trading in securities generally on Nasdaq shall have been suspended
or materially limited or minimum prices shall have been established on such exchange, (ii) a banking moratorium shall have been declared
either by Federal or New York State authorities, (iii) a material disruption has occurred in commercial banking or securities settlement
or clearance services in the United States or (iv) there shall have occurred any outbreak or escalation of hostilities, declaration
by the United States of a national emergency or war, or other calamity or crisis the effect of which on financial markets is such as to
make it, in the sole judgment of the Placement Agents, impractical or inadvisable to proceed with the offering, sale or delivery of the
Securities on the Closing Date on the terms and in the manner contemplated by this Agreement, the Purchase Agreements, the Pricing Disclosure
Package and the Prospectus.

 

7.            Indemnity
and Contribution.

 

(a)            The
Company agrees to indemnify and hold harmless each Placement Agent, the directors, officers, employees, Affiliates and agents of each
Placement Agent and each person who controls any Placement Agent within the meaning of either the Act or the Exchange Act against any
and all losses, claims, damages or liabilities, joint or several, arising out of, or based upon any untrue statement or alleged untrue
statement of a material fact contained in the Registration Statement for the registration of the Shares as originally filed or in any
amendment thereof, or in the Final Prospectus Supplement (or any amendment or supplement thereto), any Preliminary Prospectus Supplement,
any road show as defined in Rule 433(h) under the Act (a “road show”) or any Pricing Disclosure Package (including
any Pricing Disclosure Package that has subsequently been amended), or arising out of or are based upon the omission or alleged omission
to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and agrees
to reimburse each such indemnified party, as incurred, for any legal or other expenses reasonably incurred by them in connection with
investigating or defending any such loss, claim, damage, liability or action; provided, however, that the Company will not be liable
in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any such untrue statement
or omission or alleged untrue statement or omission made therein in reliance upon and in conformity with written information furnished
to the Company by or on behalf of any Placement Agent specifically for inclusion therein, it being understood and agreed that the only
such information furnished by or on behalf of any Placement Agent consists of the information described as such in Section 7(b) hereof.
This indemnity agreement will be in addition to any liability which the Company may otherwise have.

 

    	 	22	 

     

    

 

(b)            Each
Placement Agent severally and not jointly agrees to indemnify and hold harmless the Company, each of its directors, each of its officers
who signs the Registration Statement, and each person who controls the Company within the meaning of either the Act or the Exchange Act,
to the same extent as the indemnity from the Company to each Placement Agent set forth in paragraph 7(a) above, but only with reference
to written information relating to such Placement Agent furnished to the Company by or on behalf of such Placement Agent specifically
for inclusion in the documents referred to in the foregoing indemnity; and each Placement Agent agrees to reimburse each such indemnified
party for any documented legal fees or other expenses reasonably incurred by them in connection with investigating or defending any such
loss, claim, damage, liability or action. This indemnity agreement will be in addition to any liability which any Placement Agent may
otherwise have. The Company acknowledges that there has been no information furnished in writing by or on behalf of the several Placement
Agents for inclusion in the documents referred to in the foregoing indemnity other than the first sentence of the first paragraph under
the caption “—Other Relationships” in the Plan of Distribution section in each of the Final Prospectus Supplement (or
any amendment or supplement thereto) and the Preliminary Prospectus Supplement .

 

(c)            Promptly
after the receipt by any person in respect of which indemnification may be sought pursuant to either Section 7(a) or 7(b) above
of notice of the commencement of any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand,
such person (the “Indemnified Person”) will, if a claim in respect thereof is to be made against whom such indemnification
may be sought (the “Indemnifying Person”) notify the Indemnifying Person in writing as promptly as reasonably practicable
of the commencement thereof; provided that the failure so to notify the Indemnifying Person (i) will not relieve it from any
liability that it may have under this Section 7 unless and to the extent that it did not otherwise learn of such action and such
failure results in the forfeiture by the Indemnifying Person of substantial rights and defenses and (ii) will not, in any event,
relieve the Indemnifying Person from any obligations to an Indemnified Person other than the indemnification obligation provided in Section 7(a) or
Section 7(b) above. If any such proceeding shall be brought or asserted against an Indemnified Person and it shall have notified
the Indemnifying Person thereof, the Indemnifying Person shall be entitled to appoint counsel of the Indemnifying Person’s choice
at the Indemnifying Person’s expense to represent the Indemnified Person in any action, and any others entitled to indemnification
pursuant to this Section that the Indemnifying Person may designate in such action, for which indemnification is sought (in which
case the Indemnifying Person shall not thereafter be responsible for the fees and expenses of any separate counsel retained by the Indemnified
Person or Indemnified Persons except as set forth below); provided, however, that such counsel shall be reasonably satisfactory to
the Indemnified Person. Notwithstanding the Indemnifying Person’s election to appoint counsel to represent the Indemnified Person
in an action, the Indemnified Person shall have the right to employ separate counsel (including local counsel), and the Indemnifying Person
shall bear the reasonable fees, costs and expenses of such separate counsel if (A) the use of counsel chosen by the Indemnifying
Person to represent the Indemnified Person would present such counsel with a conflict of interest, (B) the actual or potential defendants
in, or targets of, any such action include both the Indemnified Person and the Indemnifying Person and the Indemnified Person shall have
reasonably concluded that there may be legal defenses available to it and/or other Indemnified Persons which are different from or additional
to those available to the Indemnifying Person, (C) the Indemnifying Person shall not have employed counsel satisfactory to the Indemnified
Person to represent the Indemnified Person within a reasonable time after notice of the institution of such action or (D) the Indemnifying
Person shall authorize the Indemnified Person to employ separate counsel at the expense of the Indemnifying Person. It is understood and
agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable
for the reasonable fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons and
that all such reasonable fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for one or more of
the Placement Agents and any of their affiliates, directors and officers and their control persons, if any, shall be designated in writing
by the Placement Agents, as applicable, and any such separate firm for the Company, its directors, its officers who signed the Registration
Statement and its control persons, if any, shall be designated in writing by the Company. An Indemnifying Person will not, without the
prior written consent of the Indemnified Persons, settle or compromise or consent to the entry of any judgment with respect to any pending
or threatened claim, action, suit or proceeding in respect of which indemnification or contribution may be sought hereunder (whether or
not the Indemnified Persons are actual or potential parties to such claim or action) unless such settlement, compromise or consent includes
(i) an unconditional release of each Indemnified Person from all liability arising out of such claim, action, suit or proceeding;
and (ii) does not include a statement as to, or an admission of, fault, culpability or a failure to act, by or on behalf of any Indemnified
Person.

 

    	 	23	 

     

    

 

(d)            In
the event that the indemnity provided in paragraph (a) or (b) of this Section 7 is unavailable or insufficient to hold
harmless an Indemnified Person for any reason, then each Indemnifying Person agrees to contribute to the aggregate losses, claims, damages
and liabilities (including legal or other expenses reasonably incurred in connection with investigating or defending the same) (collectively,
 “Losses”) to which the Company and one or more of the Placement Agents may be subject in such proportion as is appropriate
to reflect the relative benefits received by the Company, on the one hand, and the Placement Agents, on the other, from the offering and
sale of the Shares pursuant to this Agreement. If the allocation provided by the immediately preceding sentence is unavailable for any
reason, the Company and the Placement Agents severally shall contribute in such proportion as is appropriate to reflect not only such
relative benefits but also the relative fault of the Company, on the one hand, and the Placement Agents, on the other, in connection with
the statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. Benefits received by
the Company shall be deemed to be equal to the total net proceeds from the sale of the Shares (before deducting expenses) received by
it as set for the on the cover page of the Final Prospectus Supplement, and benefits received by the Placement Agents shall be deemed
to be equal to the total Placement Fee. Relative fault of the Company, on the one hand, and the Placement Agents, on the other, shall
be determined by reference to, among other things, whether any untrue or any alleged untrue statement of a material fact or the omission
or alleged omission to state a material fact relates to information supplied by each such party, the intent of the parties and their relative
knowledge, access to information and opportunity to correct or prevent such untrue statement or omission.

 

(e)            In
no case shall any Placement Agent (except as may be provided in any agreement among Placement Agents relating to the offering of the Securities)
be responsible for any amount pursuant to this paragraph 7(e) in excess of the Placement Fee. The Company and the Placement Agents
agree that it would not be just and equitable if contribution were determined by pro rata allocation or any other method of allocation
which does not take account of the equitable considerations referred to above. Notwithstanding the provisions of this paragraph 7(e),
no person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 7, each person who controls
a Placement Agent within the meaning of either the Act or the Exchange Act and each director, officer, employee and agent of a Placement
Agent shall have the same rights to contribution as such Placement Agent, and each person who controls the Company within the meaning
of either the Act or the Exchange Act, each officer of the Company who shall have signed the Registration Statement and each director
of the Company shall have the same rights to contribution as the Company, subject in each case to the applicable terms and conditions
of this paragraph 7(e).

 

    	 	24	 

     

    

 

(f)            The
remedies provided for in this Section 7 are not exclusive and shall not limit any rights or remedies which may otherwise be available
to any Indemnified Person at law or in equity.

 

8.            Payment
of Expenses.

 

(a)            The
Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, will pay or reimburse
if paid by any Placement Agent all reasonable and documented costs and expenses incident to the performance of the Company’s obligations
under this Agreement and in connection with the transactions contemplated hereby, including but not limited to costs and expenses of or
relating to (i) the preparation, printing, filing, delivery and shipping of the Registration Statement, the Pricing Disclosure Package
and the Final Prospectus Supplement, and any amendment or supplement to any of the foregoing and the printing and furnishing of copies
of each thereof to the Placement Agents and dealers (including costs of mailing and shipment), (ii) the registration, sale and delivery
of the Securities including any stock or transfer taxes and stamp or similar duties payable upon the sale or delivery of the Securities
and the printing, delivery, shipping of the certificates representing the Securities, (iii) the fees and expenses of any transfer
agent or registrar for the Securities, (iv) fees, disbursements and other charges of counsel for the Company, (v) listing fees,
if any, for the listing or quotation of the Shares (including the Warrant Shares) on Nasdaq, (vi) fees and disbursements of the Company’s
auditor incurred in delivering the letters described in Section 4(f) hereof, and (vii) the costs and expenses of the Company
in connection with the marketing of the Offering and the sale of the Securities to prospective Investors including, but not limited to,
those related to any presentations or meetings undertaken in connection therewith, in each case, including applicable VAT, if any.

 

(b)            The
Company agrees with the Placement Agents to pay (directly or by reimbursement) the costs and expenses of the Company in connection with
the marketing of the Offering and the sale of the Securities to prospective Investors including, but not limited to, those related to
any presentations or meetings undertaken in connection therewith.

 

(c)            It
is understood that except as provided in this Section 6, Section 7 and Section 8 hereof, the Placement Agents shall pay
all of their own expenses, including the fees and expenses of their own advisers, counsel, accountants and other experts, if any, and
all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement
other than as separately agreed in writing with the Placement Agents.

 

9.            Notices.
All notices and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if mailed or
transmitted and confirmed by any standard form of communication, and:

 

	If to the Placement Agents:	 	Citigroup
Global Markets Inc.

388 Greenwich Street

New York, New York 10013

Facsimile: (646) 291-1469

Attention: General Counsel
	 	 	 

 

    	 	25	 

     

    

 

	 	 	B. Riley Securities, Inc.
	 	 	11100 Santa Monica Blvd., Suite 800

Los Angeles, California 90025

Attention:
General Counsel
	 	 	Email: legal@brileyfin.com
	 	 	 
	 	 	Piper
Sandler & Co.

800 Nicollet Mall

Minneapolis, Minnesota 55402

Attention: Legal Department

Email: legalcapmarkets@psc.com

	 	 	 
	with a copy to:	 	Latham & Watkins
LLP
	 	 	1271 Avenue of the Americas

New York, New York 10020

Attention: Benjamin Cohen
	 	 	Email:benjamin.cohen@lw.com
	 	 	 
	If to the Company:	 	Lilium N.V.
	 	 	c/o Lilium Aviation Inc.

2385 N.W. Executive Center Drive, Suite 300

Boca Raton, Florida 33431

Attention: Roger Franks

Email: roger.franks@lilium.com

	 	 	 
	with copies (which shall not constitute
notice) to:
	 
	 	 	Ropes & Gray LLP

1211 Avenue of the Americas

New York, New York 10036-8704

Attention: Carl Marcellino

Email: carl.marcellino@ropesgray.com

	 	 	 
	 	 	

Freshfields Bruckhaus Deringer US LLP

601 Lexington Avenue

New York, NY 10022

Attention: Valerie Ford Jacob

Email: valerie.jacob@freshfields.com

 

Any party hereto may change the address for receipt
of communications by giving written notice to the others.

 

10.            Miscellaneous.

 

(a)            Governing
Law. This Agreement and any claim, controversy or dispute arising under or relating to this Agreement shall be governed by, and construed
in accordance with, the laws of the State of New York.

 

    	 	26	 

     

    

 

(b)            Submission
to Jurisdiction. The Company hereby submits to the exclusive jurisdiction of the U.S. federal and New York state courts in the Borough
of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby. The Company waives any objection which it may now or hereafter have to the laying of venue of any such suit or proceeding in such
courts. The Company agrees that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding
upon the Company and may be enforced in any court to the jurisdiction of which Company is subject by a suit upon such judgment. The Company
irrevocably designates and appoints Lilium Aviation Inc., 2385 N.W. Executive Center Drive, Suite 300, Boca Raton, Florida 33431,
as its authorized agent in the United States upon which process may be served in any such suit or proceeding, and agrees that service
of process upon such authorized agent be certified or registered mail, or by personal delivery by Federal Express, to such authorized
agent shall be deemed in every respect effective service of process upon the Company in any such suit or proceeding. The Company further
agrees to take any and all actions as may be necessary to maintain such designation and appointment of such agent in full force and effect
for a period of five years from the date of this Agreement.

  

(c)            Waiver
of Jury Trial. Each of the parties hereto hereby waives any right to trial by jury in any suit or proceeding arising out of or relating
to this Agreement.

 

(d)            Judgment
Currency. The Company agrees to indemnify each Placement Agent, its directors, officers, affiliates and each person, if any, who controls
such Placement Agent within the meaning of Section 17 of the Act or Section 20 of the Exchange Act, against any loss incurred
by such Placement Agent as a result of any judgment or order being given or made for any amount due hereunder and such judgment or order
being expressed and paid in a currency (the “Judgment Currency”) other than U.S. dollars and as a result of any variation
as between (i) the rate of exchange at which the U.S. dollar amount is converted into the Judgment Currency for the purpose of such
judgment or order, and (ii) the rate of exchange at which such indemnified person is able to purchase U.S. dollars with the amount
of the Judgment Currency actually received by the indemnified person. The foregoing indemnity shall constitute a separate and independent
obligation of the Company and shall continue in full force and effect notwithstanding any such judgment or order as aforesaid. The term
 “rate of exchange” shall include any premiums and costs of exchange payable in connection with the purchase of, or conversion
into, the relevant currency.

 

(e)            Waiver
of Immunity. To the extent that the Company or either of the Placement Agents has or hereafter may acquire any immunity (sovereign
or otherwise) from jurisdiction of any court of (i) the Netherlands, or any political subdivision thereof, (ii) the United States
or the State of New York, (iii) any jurisdiction in which it owns or leases property or assets or from any legal process (whether
through service of notice, attachment prior to judgment, attachment in aid of execution, execution, set-off or otherwise) with respect
to themselves or their respective property and assets or this Agreement, the Company hereby irrevocably waives such immunity in respect
of its obligations under this Agreement to the fullest extent permitted by applicable law.

 

11.            Persons
Entitled to Benefit of Agreement. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective
successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Placement Agent referred
to in Section 7 hereof. Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable
right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Securities from the Company
shall be deemed to be a successor merely by reason of such purchase.

 

12.            Counterparts.
This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of telecommunication), each
of which shall be an original and all of which together shall constitute one and the same instrument.

 

    	 	27	 

     

    

 

13.            Survival.
The respective indemnities, rights of contribution, representations, warranties and agreements of the Company and the Placement Agents
contained in this Agreement or made by or on behalf of the Company or the Placement Agents pursuant to this Agreement or any certificate
delivered pursuant hereto shall survive the delivery of and payment for the Securities and shall remain in full force and effect, regardless
of any termination of this Agreement or any investigation made by or on behalf of the Company or the Placement Agents.

 

14.            Certain
Defined Terms. For purposes of this Agreement, except where otherwise expressly provided, the following terms shall have the meanings
indicated.

 

“Action” means any
action, lawsuit, complaint, claim, petition, suit, audit, examination, assessment, arbitration, mediation or inquiry, or any proceeding
or investigation, by or before any Governmental Authority.

 

“Affiliate” shall
have the meaning set forth in Rule 405 under the Act.

 

“Base Prospectus”
shall mean the prospectus referred to in paragraph 1(a) above contained in the Registration Statement at the Effective Date.

 

“business day” shall
mean any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions or trust companies are authorized
or obligated by law to close in New York City.

 

“Code” shall mean
the Internal Revenue Code of 1986, as amended, and applicable regulations promulgated thereunder.

 

“Commission” shall
mean the Securities and Exchange Commission.

 

“Effective Date” shall
mean each date and time that the Registration Statement and any post-effective amendment or amendments thereto became or become effective.

 

“Execution Time” shall
mean the date and time that this Agreement is executed and delivered by the parties hereto.

 

“Final Prospectus Supplement”
shall mean the prospectus supplement relating to the Securities that was filed pursuant to Rule 424(b) after the Execution Time,
together with the Base Prospectus.

 

“Free Writing Prospectus”
shall mean a free writing prospectus, as defined in Rule 405.

 

“Governmental Authority”
means any federal, state, provincial, municipal, local, international, supranational or foreign government, governmental authority, regulatory
or administrative agency (which for the purposes of this Agreement shall include the Commission), governmental commission, department,
board, bureau, agency, court, arbitral tribunal, securities exchange or similar body or instrumentality thereof.

 

“Initial Sale Time”
shall mean 8 a.m. (Eastern time) on the date of this Placement Agency Agreement.

 

“Issuer Free Writing Prospectus”
shall mean an issuer free writing prospectus, as defined in Rule 433.

 

    	 	28	 

     

    

 

“Organizational Documents”
means the Company’s Deed of Conversion and Amendment to the Articles of Association of Lilium B.V. into Lilium N.V., filed with
the Commercial Register of the Netherlands Chamber of Commerce or similar organizational documents of the Company’s Subsidiaries.

  

“Person” means any
person or entity, whether a natural person, trustee, corporation, partnership, limited partnership, limited liability company, trust,
unincorporated organization, business association, firm, joint venture, governmental agency or authority.

 

“Preliminary Prospectus Supplement”
shall mean any preliminary prospectus supplement to the Base Prospectus which describes the Shares and the offering thereof and is used
prior to filing of the Final Prospectus Supplement, together with the Base Prospectus.

 

“Pricing Disclosure Package”
shall mean (i) the Base Prospectus together with the Preliminary Prospectus Supplement dated November 18, 2022, (ii) the
pricing information set forth in Exhibit C hereto and (iii) any other Free Writing Prospectus that the parties hereto shall
hereafter expressly agree in writing to treat as part of the Pricing Disclosure Package.

 

“Prospectus Delivery Period”
shall mean such period of time after the first date of the public offering of the Securities as in the opinion of counsel for the Placement
Agents a prospectus for the Securities is required by law to be delivered (whether physically or through compliance with Rule 172
under the Act or any similar rule) in connection with the offering or sale of Securities by any Placement Agent or dealer.

 

“Registration Statement”
shall mean the registration statement referred to in paragraph 1(a) above, including exhibits and financial statements, as amended
on each Effective Date and, in the event any post-effective amendment thereto becomes effective prior to the Closing Date, shall also
mean such registration statement as so amended.

 

“Rule 158”, “Rule 163”,
 “Rule 164”, “Rule 172”, “Rule 405”, “Rule 415”,
 “Rule 424”, “Rule 433”, “Rule 456” and “Rule 457”
refer to such rules under the Act.

 

“Tax Return” means
any return, declaration, report, statement, information statement or other document filed or required to be filed with any Governmental
Authority with respect to Taxes, including any claims for refunds of Taxes, any information returns and any amendments or supplements
of any of the foregoing.

 

“Taxes” means all
federal, state, local, foreign or other taxes imposed by any Governmental Authority, including all income, gross receipts, license, payroll,
employment, excise, severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital stock, ad valorem,
value added, inventory, franchise, profits, withholding, social security (or similar), unemployment, disability, real property, personal
property, sales, use, transfer, registration, alternative or add-on minimum, or estimated taxes, and including any interest, penalty,
or addition thereto.

 

15.            Recognition
of the U.S. Special Resolution Regimes.

 

(a)            In
the event that any Placement Agent that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the
transfer from such Placement Agents of this Agreement, and any interest and obligation in or under this Agreement, will be effective to
the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and
obligation, were governed by the laws of the United States or a state of the United States.

 

    	 	29	 

     

    

 

(b)            In
the event that any Placement Agent that is a Covered Entity or a BHC Act Affiliate of such Placement Agent becomes subject to a proceeding
under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Placement Agent are permitted
to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement
were governed by the laws of the United States or a state of the United States.

 

As used in this Section 15:

 

“BHC Act Affiliate”
has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k).

 

“Covered Entity” means
any of the following:

 

(i)             a
 “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);

 

(ii)            a
 “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a
 “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).

 

“Default Right” has
the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1,
as applicable.

 

“U.S. Special Resolution Regime”
means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank
Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

 

16.            Compliance
with USA Patriot Act. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26,
2001)), the Placement Agents are required to obtain, verify and record information that identifies their respective clients, including
the Company, which information may include the name and address of their respective clients, as well as other information that will allow
the Placement Agents to properly identify their respective clients.

 

17.            Amendments
or Waivers. No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall
in any event be effective unless the same shall be in writing and signed by the parties hereto or thereto as the case may be.

 

18.            Electronic
Signatures. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal
ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com)
or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and
effective for all purposes.

 

19.            Headings.
The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation
of, this Agreement.

 

[Signature Page Follows]

 

    	 	30	 

     

    

 

If the foregoing correctly sets forth your understanding
of our agreement, please so indicate in the space provided below for that purpose, whereupon this letter and your acceptance shall constitute
a binding agreement among the Company and the Placement Agents.

 

		Very truly yours,
	 	 
	 	LILIUM N.V.
	 	 	 
	 	By:	/s/ Geoffrey Richardson

	 	Name: Geoffrey Richardson
	 	Title: Chief Financial Officer

 

[Signature Page to
Placement Agent Agreement]

 

    	 		 

     

    

 

The foregoing Agreement is hereby confirmed and accepted as
of the date first above written.

 

	CITIGROUP GLOBAL MARKETS INC.	 
	 	 
	By:	/s/ Kevin Cox	 
	Name: Kevin Cox	 
	Title: Managing Director	 

 

	B. RILEY SECURITIES, INC.	 
	 	 
	By:	/s/ Patrice McNicoll	 
	Name: Patrice McNicoll	 
	Title: Co-Head of Investment Banking	 

 

	PIPER SANDLER & CO.	 
	 	 
	By:	 /s/ Matthew Wolfe	 
	Name: Matthew Wolfe	 
	Title: Managing Director, ECM	 

 

[Signature Page to Placement Agent Agreement]

 

    	 		 

     

    

 

Exhibit A

 

Form of Warrant

 

    	 		 

     

    

 

Exhibit B

 

Form of Purchase Agreement

 

    	 		 

     

    

 

EXHIBIT C

 

Pricing Information

 

		i.	Number
of Shares: 22,499,997

 

		ii.	Offering
Price per Share: $1.30

 

		iii.	Number
of Warrants: 11,249,997

 

		iv.	Warrant
Exercise Price per whole Share: $1.30

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]